EXOSENS
REVEAL THE INVISIBLE

HALF-YEAR FINANCIAL REPORT 2026

INCLUDING:

2026 half-year activity report
Condensed Consolidated Interim Financial Statements as at 30 June 2026
Statutory Auditors' review report on the 2026 half-yearly financial information
Statement by the persons responsible for the 2026 half-year financial report

Contents

01 HALF-YEAR ACTIVITY REPORT 2026

Introduction

EXOSENS is an international high-tech group with over 85 years of experience in the innovation, development, manufacture and sale of high-end electro-optical technologies in the field of Amplification, Detection and Imaging. The Group's broad portfolio of detectors and imaging solutions encompasses image intensifier tubes, digital cameras that use various wavelengths, as well as ion, electron, neutron and gamma-ray detectors. EXOSENS provides tailor-made solutions to meet the needs of end users facing complex issues in challenging environments in the areas of defence and surveillance, life sciences, nuclear and industrial control.

The Group is the leader in the Light Amplification market (excluding the United States) and one of the leaders in the Detection & Imaging markets that it targets, which present attractive growth prospects.

The Group's activities are organised into two segments (which also correspond to the segmentation used by the Group for reporting purposes):

- Amplification, which accounted for 70% of the Group's revenue in the first half of 2026, consisting of systems using the amplification of electrons to produce an image. The majority of Amplification sales come from selling components and modules for integration into equipment used in the defence sector (primarily by armed forces and homeland security services). Following the Group's acquisition of NVLS in July 2025, this segment now also includes sales of man-portable optronic equipment, such as night vision goggles and thermal weapon sights;
- Detection & Imaging, which accounted for 31% of the Group's revenue in the first half of 2026, consisting of systems for detecting optical or electronic signals or generating an image from radiation in different wavelength bands of the electromagnetic spectrum. The majority of sales in this segment come from the sale of components and modules for integration into instruments and systems in commercial markets. These markets encompass sectors such as nuclear power generation, research laboratories, the oil and gas industry, the agrifood industry, life sciences, semiconductor inspection, electronics and recycling. The segment also includes sales of imaging systems for defence and surveillance applications, in particular drones and counter-drone systems.

1.1 HIGHLIGHTS

Seasonality

The Group's revenue is affected by the seasonal nature of the products sold to its customers. Orders and revenue are typically higher at year-end, particularly for Amplification products, which are mainly associated with the defence sector and affected in particular by year-end budget cycles. By contrast, order intake and revenue are generally lowest in the first quarter. The Group therefore records significantly higher revenue in the final quarter of the year, while first-quarter revenue is generally lower than in the other quarters and cannot be extrapolated to the full financial year.

Income and expenses arising from ordinary activities that the Group receives or incurs on a seasonal, cyclical or occasional basis are recognised in accordance with the same rules as those used for the annual financial statements. They are neither accrued nor deferred in quarterly reporting. Expenses and income invoiced on an annual basis are included in interim information on a pro rata basis. Lastly, provisions for risks arising during the first half of the year are recorded in the accounts of the period.

Highlights

Contract with ACTinBlack for the supply of 5G image intensifier tubes

On 12 January 2026, EXOSENS announced that ACTinBlack Group, one of Europe's leading manufacturers of advanced night vision systems, had ordered more than 7,000 5G image intensifier tubes for use by European special forces. This contract was secured only a few months after the official unveiling of 5G, EXOSENS' new technology, underscoring its rapid market adoption. The tubes are scheduled for delivery in 2027 and 2028. They will be integrated into night vision goggles intended for European special forces end users.

US Army BiNOD contract for the supply of advanced night vision solutions

On 2 March 2026, the Group was awarded a US Army BiNOD contract with a maximum value of 352.6 million US dollars. This Indefinite Delivery/Indefinite Quantity (IDIQ) contract covers the development, production and testing of the US Army's BiNOD (Binocular Night Observation Device) binocular night vision devices until 27 February 2033.

The award marks a major milestone in EXOSENS' expansion in the United States, where the Group's scalable industrial footprint supports its development in the world's most demanding single market for night vision devices.

Doubling of cooled infrared camera production capacity

The Group plans to double its production capacity for cooled infrared cameras during 2026 in response to accelerating global demand for advanced digital imaging solutions, particularly in long-range surveillance and counter-drone applications.

Manufactured in France, EXOSENS' high-performance cooled infrared imaging solutions are designed for seamless integration into a wide range of platforms, such as gimbals, turrets, surveillance payloads and protection systems deployed on drones, robots and vehicles. They are increasingly being adopted by a broad range of industry players, from major defence contractors to leading OEMs and autonomous systems developers.

Unification of the Group's brands under the single EXOSENS brand

During the first half of 2026, the Group began gradually consolidating its entire product portfolio under the single EXOSENS brand. This strategic initiative builds on the Group's growth and the integration of the companies acquired in recent years. Against this backdrop, the Photonis, Telops and Xenics brands were fully impaired (see Notes 10 and 16 to the condensed consolidated interim financial statements). This change is intended to strengthen the consistency, visibility and recognition of the EXOSENS brand among its customers and partners.

New financing from the European Investment Bank (EIB)

On 24 June 2026, the Group entered into a 140 million euro financing agreement with the European Investment Bank (EIB), backed by the InvestEU programme. This financing facility is intended to support the Group's research, development and innovation activities, as well as selected industrial investments serving the European defence, surveillance and industrial end markets. This transaction enables the Group to diversify its sources of financing and support the implementation of its growth and innovation strategy.

Contract to supply 17,000 image intensifier tubes to the Czech Armed Forces

On 29 June 2026, EXOSENS announced that BROLIS had ordered 17,000 image intensifier tubes for the Czech Armed Forces, to be delivered by 2032. Under the agreement, EXOSENS will deliver its high-performance image intensifier tubes to BROLIS through 2032, supporting the modernisation of the Czech Armed Forces' night vision capabilities while providing the Group with long-term revenue visibility.

This programme represents the largest procurement of image intensifier tubes ever undertaken by the Czech Republic, demonstrating the field-proven operational performance, reliability and quality of EXOSENS' advanced night vision technologies. It further strengthens the Group's position as a trusted, ITAR-free supplier of mission-critical night vision components to NATO armed forces and leading defence system integrators.

Acquisitions

Acquisition of Emberion

On 24 April 2026, the EXOSENS Group acquired 100% of the shares in Emberion, a company incorporated under Finnish law and located at Metsänneidonkuja 8, 02130 Espoo. Emberion specialises in the manufacture of next-generation infrared sensors based on quantum dot technology. This acquisition enables EXOSENS to strengthen its position in the infrared imaging market, particularly for Defence & Surveillance and Industrial Control applications.

Investment in Adelphi Technology

On 13 May 2026, the EXOSENS Group acquired a 29.99% interest in Adelphi Technology Inc., a US company specialising in the design and manufacture of compact neutron generators. This investment supports the development of the Group's neutron imaging business.

1.2 ANALYSIS OF THE GROUP'S RESULTS

CONDENSED INCOME STATEMENT

(in € millions)	Note	1st half 2026	1st half 2025 restated
Revenue	6	**253.1**	**219.5**
Cost of sales		-57.7	-48.9
Other purchases and external expenses	7	-39.5	-35.0
Taxes		-1.7	-1.1
Employee benefit expense	8	-77.0	-67.6
Other operating income/(expense)	9	0.4	0.7
Depreciation, amortisation, impairment and provision charges	10	-46.2	-18.5
Including PPA amortisation and brand impairment	10	*36.1*	*6.5*
CURRENT OPERATING PROFIT/(LOSS)		**31.2**	**49.1**
Current operating profit/(loss) excluding PPA amortisation and brand impairment	*11*	***67.3***	***55.6***
Other income/(expenses)	11	0.0	0.0
OPERATING PROFIT/(LOSS)		**31.2**	**49.0**
Operating profit/(loss) excluding PPA amortisation and brand impairment		***67.3***	***55.6***
Net finance income/(expense)	12	-6.0	-8.3
Profit/(loss) before tax		**25.2**	**40.7**
Profit/(loss) before tax excluding PPA amortisation and brand impairment		***61.3***	***47.2***
Income tax	13	-9.9	-11.1
Profit/(loss) from discontinued operations attributable to owners of the parent		**0.0**	**-1.7**
PROFIT/(LOSS)		**15.3**	**27.9**
Profit/(loss) excluding PPA amortisation and brand impairment		***43.9***	***34.5***

The figures for the six months ended 30 June 2025 are restated following the application of IFRS 5.

Key performance indicators

The Group uses key financial and non-financial measures to analyse the performance of its business. The key performance indicators used include revenue, adjusted gross margin, adjusted EBITDA and adjusted EBIT.

Adjusted gross margin is the difference between the selling price and the cost of products and services sold (including employee costs).

Adjusted EBITDA is defined as operating profit adjusted to exclude (i) depreciation, amortisation and impairment of non-current assets, net of reversals; (ii) non-recurring income and expenses presented in the consolidated income statement under "Other income" and "Other expenses"; and (iii) the effects of items that do not reflect the Group's core operating performance, such as business restructuring and adaptation costs and expenses associated with share-based payments (IFRS 2).

Adjusted EBIT is defined as operating profit adjusted to exclude (i) non-recurring income and expenses presented in the consolidated income statement under "Other income" and "Other expenses" and (ii) the effects of items that do not reflect the Group's core operating performance, such as business restructuring and adaptation costs and expenses associated with share-based payments (IFRS 2). Adjusted EBIT excludes depreciation and amortisation of the portion of non-current assets corresponding to purchase price allocations. All other depreciation, amortisation and impairment, net of reversals, are included.

Adjusted gross margin, adjusted EBITDA and adjusted EBIT are not standard accounting measures with a generally accepted definition. They should not be considered substitutes for operating profit, net profit or cash flow from operating activities or an indicator of liquidity. Other companies may calculate adjusted gross margin, adjusted EBITDA or adjusted EBIT using definitions different from those used by the Group.

Revenue

(in € millions)	1st half 2026	1st half 2025 restated	Change *(%)*	Like-for-like *(%)*
Amplification	176.3	157.9	+11.6%	+10.0%
Detection & Imaging	77.4	62.3	+24.3%	14.6%
Eliminations and other	-0.6	-0.7	-	-
TOTAL REVENUE	**253.1**	**219.5**	**+15.3%**	**+11.4%**

In the first half of 2026, consolidated revenue reached 253.1 million euros, representing significant growth of +15.3% (+33.6 million euros) compared with the first half of 2025, including like-for-like growth of +11.4%, driven by strong demand in the Defence & Surveillance markets.

Revenue – Amplification

In the first half of 2026, revenue in the Amplification segment amounted to 176.3 million euros, representing significant growth of +11.6% compared with the first half of 2025, driven by higher sales volumes, improved yields and a more favourable product mix. Like-for-like growth was solid, reaching +10.0% in the first half of 2026.

Revenue – Detection & Imaging

In the first half of 2026, revenue in the Detection & Imaging segment reached 77.4 million euros, representing growth of +24.3% compared with the first half of 2025.

This performance reflects the scope effect arising from the contribution of acquisitions completed in 2025 (Noxant and Phasics), as well as strong like-for-like growth of +14.6%, driven by sustained demand in the Defence & Surveillance markets, particularly in drone and counter-drone applications, and solid momentum in Nuclear.

Adjusted gross margin

In the first half of 2026, EXOSENS recorded a strong increase in adjusted gross margin at Group level and across both segments, mainly due to higher sales volumes, improved yields and a favourable product mix. The Group's adjusted gross margin reached 129.9 million euros in the first half of 2026, representing an increase of +16.5% compared with the first half of 2025. The Group's adjusted gross margin rate reached +51.3%, representing a significant improvement of +53 basis points compared with the first half of 2025.

The table below provides a breakdown of the Group's adjusted gross margin by segment for the six months ended 30 June 2026 and 30 June 2025 restated:

	1st half 2026		1st half 2025 restated		Change
	(in € millions)	% of sales	*(in € millions)*	% of sales	*(in %)*
Amplification	92.6	52.5%	81.2	51.5%	14.0%
Detection & Imaging	37.2	48.1%	30.3	48.7%	22.8%
Eliminations and other	0.1	-	-0.1	-	-
ADJUSTED GROSS MARGIN	**129.9**	**51.3%**	**111.5**	**50.8%**	**16.5%**

Adjusted gross margin – Amplification

In the first half of 2026, the Amplification segment's adjusted gross margin reached 92.6 million euros (+14.0% compared with the first half of 2025), representing a margin of 52.5% (compared with 51.5% in the first half of 2025). This strong increase in the margin rate was mainly driven by higher sales volumes, improved yields and a more favourable product mix.

Adjusted gross margin – Detection & Imaging

In the first half of 2026, the Detection & Imaging segment's adjusted gross margin reached 37.2 million euros (+22.8% compared with the first half of 2025), representing a margin of 48.1% (compared with 48.7% in the first half of 2025). This decrease in the margin rate was mainly attributable to a less favourable product mix, reflecting lower sales of higher-margin products such as advanced detectors for Life Sciences.

Current operating profit/(loss)

Current operating profit fell from 49.1 million euros in the first half of 2025 to 31.2 million euros in the first half of 2026, representing a change of -17.8 million euros (-36.4%).

The decrease in current operating profit was mainly attributable to a brand impairment charge of 28.2 millions euros.

Operating profit/(loss)

The Group recorded operating profit of 31.2 million euros in the first half of 2026, compared with 49.0 million euros in the first half of 2025, representing a change of -36.3% (-17.8 million euros).

This change was attributable to a brand impairment charge of 28.2 millions euros.

Adjusted EBITDA and Adjusted EBIT

Adjusted EBITDA rose from 70.6 million euros in the first half of 2025 to 83.6 million euros in the first half of 2026, representing strong growth of +18.3% (+12.9 million euros). Consequently, the Group's adjusted EBITDA margin improved to 33.0% in the first half of 2026, from 32.2% in the first half of 2025, a change of +84 basis points.

Adjusted EBIT rose from 60.2 million euros in the first half of 2025 to 71.8 million euros in the first half of 2026, representing growth of +19.2% (+11.6 million euros). Consequently, the adjusted EBIT margin increased to 28.4% in the first half of 2026, from 27.4% in the first half of 2025, a change of +92 basis points.

RECONCILIATION OF OPERATING PROFIT TO ADJUSTED EBITDA AND ADJUSTED EBIT

(in € millions)	1st half 2026	1st half 2025 restated
Operating profit/(loss)	**31.2**	**49.0**
Depreciation, amortisation and impairment – net*	47.9	17.1
Other income and expenses	0.0	0.0
EBITDA	**79.0**	**66.1**
Share-based payments	3.0	0.9
Non-recurring costs	1.6	3.5
Adjusted EBITDA	**83.6**	**70.6**
Depreciation, amortisation and impairment excluding PPA amortisation and brand impairment	-11.8	-10.4
Adjusted EBIT	**71.7**	**60.2**

* *This amount corresponds to the first two lines of the table in Note 10 to the condensed consolidated interim financial statements.*

Net finance income/(expense)

Net finance expense decreased from 8.3 million euros in the first half of 2025 to 6.0 million euros in the first half of 2026, an improvement of +2.3 million euros.

The improvement in net finance expense in the first half of 2026 was mainly attributable to lower interest expense on the Group's debt, driven by the decline in Euribor and the reduction in the margin applicable to certain financing facilities. Net finance expense was also reduced by a favourable foreign exchange effect and a lower net expense on derivative instruments. These factors were partly offset by the remeasurement of a put option.

Profit/(loss)

Net profit fell from 27.9 million euros in the first half of 2025 to 15.3 million euros in the first half of 2026, representing a change of -12.6 million euros, for the reasons described above.

Excluding PPA amortisation and brand impairment, net profit reached 43.9 millions euros in the first half of 2026, compared with 34.5 millions euros in the first half of 2025, representing a change of +16.9 millions euros.

	30 June 2026	30 June 2025
PROFIT/(LOSS) (IN EUROS)	**15,339,685**	**27,909,421**
Profit/(loss) from continuing operations	15,339,685	29,611,974
Profit/(loss) from discontinued operations	0	-1,702,553
Weighted average number of shares	50,441,791	50,782,552
BASIC EARNINGS PER SHARE (IN EUROS)	**0.30**	**0.55**
Basic earnings per share from continuing operations (in euros)	0.30	0.58
Basic earnings per share from discontinued operations (in euros)	0.00	-0.03
PROFIT/(LOSS) (EXCLUDING BRAND IMPAIRMENT) (IN EUROS)	**35,936,069**	
Basic earnings per share (excluding brand impairment) (in euros)	0.71	

1.3 ANALYSIS OF THE GROUP'S BALANCE SHEET

CONSOLIDATED BALANCE SHEET

(in € millions)	30 June 2026	31 December 2025
Non-current assets	589.2	598.6
Current assets (excluding cash)	236.9	211.6
Cash and cash equivalents	68.8	68.6
TOTAL ASSETS	**895.0**	**878.9**

(in € millions)	30 June 2026	31 December 2025
Equity	450.9	445.7
Non-current liabilities	314.1	319.5
Current liabilities	130.0	113.7
TOTAL EQUITY AND LIABILITIES	**895.0**	**878.9**

1.3.1 Non-current assets

Non-current assets mainly comprise property, plant and equipment, intangible assets (including goodwill), non-current financial assets and tax receivables due after more than one year (mainly deferred tax assets).

Compared with the figures as at 31 December 2025, total non-current assets changed by -9.4 million euros. This change was mainly attributable to:

- additions to property, plant and equipment and intangible assets totalling 34.6 million euros, including right-of-use assets;
- depreciation and amortisation for the period, with an impact of -19.1 million euros;
- impairment of the Photonis, Telops and Xenics brands, with an impact of -28.2 million euros; and
- the acquisition of equity interests in Emberion and Adelphi for 4.5 million euros.

1.3.2 Current assets

Current assets, excluding cash, amounted to 236.9 million euros, an increase of 25.3 million euros compared with 31 December 2025. This change was mainly attributable to an increase of 18.2 million euros in inventories in preparation for deliveries scheduled for the second half of the year and an increase of 2.9 million euros in trade receivables resulting from strong revenue growth, partially offset by improved customer payment times.

1.3.3 Equity

The Group's equity increased by 5.2 million euros compared with 31 December 2025 to 450.9 million euros as at 30 June 2026.

The change in equity was mainly attributable to:

- total comprehensive income for the period, reflecting a profit of 15.3 million euros; and
- a dividend distribution with an impact on equity of -15.2 million euros, equivalent to €0.30 per share in respect of the 2025 financial year.

The company's issued share capital as at 30 June 2026 amounted to 21.6 million euros and consisted of ordinary shares with a nominal value of 0.425 euros each, fully subscribed and paid up. These share issues included total share premiums of 346.8 million euros.

1.3.4 Current and non-current liabilities

Current and non-current liabilities amounted to 444.1 million euros, representing a change of +10.9 million euros compared with 31 December 2025.

This increase was mainly attributable to:

- higher amounts payable to the State, with an impact of +7.9 million euros;
- higher trade payables, with an impact of +4.4 million euros;
- higher borrowings, with an impact of +3.1 million euros, mainly due to a new loan taken out by a French entity; and
- lower deferred tax liabilities, with an impact of -4.4 million euros.

As at 30 June 2026, the Group's total net debt/adjusted EBITDA ratio stood at 1.2x (unaudited).

The Group regularly monitors compliance with its financial covenants.

During the 2025 financial year and the first half of the 2026 financial year, the Group did not breach its financial covenant based on the leverage ratio.

1.4 FINANCIAL RESOURCES AND LIABILITIES

1.4.1 The Group's financial resources

The Group's main financing requirements include its working capital requirements, capital expenditure (particularly expenditure relating to research and development), interest payments and acquisition-related expenditure.

The Group's main sources of liquidity during the first half of 2026 were:

- cash flows from operating activities, which amounted to 63.9 million euros in the first half of 2026 and 50.8 million euros in the first half of 2025 (see the section entitled "Cash flows from operating activities" in this report);
- the Senior Credit Agreement, comprising two credit facilities totalling up to 450 million euros, of which 250 million euros had been drawn and 200 million euros remained undrawn; and
- the Credit Agreement entered into with the European Investment Bank (EIB), providing for a facility of up to 140 million euros, which remained undrawn as at 30 June 2026.

Credit facilities

The Senior Credit Agreement comprises the following two credit facilities, totalling up to 450 million euros:

- a euro-denominated term loan of up to 250 million euros, with a five-year term from the initial drawdown and repayable at maturity; and
- a revolving credit facility (RCF) of up to 200 million euros, with a five-year term from the initial drawdown of the term loan, any amounts drawn being repayable at the end of the applicable interest period. The facility remained undrawn as at 30 June 2026.

The Credit Agreement entered into with the European Investment Bank (EIB) provides for a facility of up to 140 million euros, with a term of up to seven years, repayable at maturity and undrawn as at 30 June 2026.

Interest and fees

Loans drawn under the Senior Credit Agreement bear interest at a floating rate based, depending on the currency of the drawdown, on either the term reference rate or the compounded reference rate, plus a margin determined by the total net debt/adjusted EBITDA ratio.

The table below presents the margin schedule applicable to each credit facility based on the debt ratio, as defined in the waiver dated 3 June 2026. The margins are reviewed every six months by testing the ratio on the last day of each half-year period, with the first test taking place six months after the Company's IPO.

The following fees apply to the revolving credit facility:

- a non-utilisation fee equal to 35% of the then-applicable margin is payable per annum; and
- a utilisation fee is payable based on the percentage utilisation:
  - > 0% and ≤ 33.33%, 0.10% per annum,
  - > 33.33% and ≤ 66.66%, 0.20% per annum,
  - > 66.66%, 0.40% per annum.

Leverage ratio (total net debt/pro forma adjusted EBITDA)	Term loan margin	Revolving credit facility margin
Greater than 2.5x	1.75%	1.35%
Greater than or equal to 2.0x and less than 2.5x	1.50%	1.10%
Greater than or equal to 1.5x and less than 2.0x	1.30%	0.90%
Greater than or equal to 1.0x and less than 1.5x	1.15%	0.75%
Greater than or equal to 0.5x and less than 1.0x	1.05%	0.65%
Less than 0.50x	0.95%	0.55%

The EIB facility has a 36-month drawdown availability period and a 12-month grace period. At the end of the grace period, a non-utilisation fee of between 0.126% and 0.315% per annum is payable, depending on the leverage ratio. The agreement allows the borrower to elect a fixed or floating interest rate. For illustrative purposes, the table below shows the interest rates that would have applied had the facility been drawn down on 15 June 2026:

Leverage ratio (total net debt/pro forma adjusted EBITDA)	Floating rate	Fixed rate
Greater than or equal to 2.0x	EUR3M + 1.52%	4.40%
Greater than or equal to 1.0x and less than 2.0x	EUR3M + 1.20%	4.08%
Less than 1.0x	EUR3M + 0.98%	3.86%

Guarantees and security interests

Under the Senior Credit Agreement, the Company is the borrower and guarantees the obligations of subsidiaries that accede to the agreement as borrowers.

The Senior Credit Agreement does not require the Group to grant security interests in favour of the Lenders.

Undertakings and restrictive clauses

The Senior Credit Agreement contains certain positive and negative undertakings, in particular undertakings not to:

- grant security interests (negative pledge);
- dispose of assets, except for assets representing no more than 10% of the Group's adjusted EBITDA per financial year and a total of 50,000,000 euros of adjusted EBITDA transferred until full repayment of the credits granted under the Senior Credit Agreement (calculated in accordance with the provisions of the Senior Credit Agreement on the basis of the Company's consolidated accounts);
- carry out certain mergers, demergers, partial transfers of assets and similar transactions;
- acquire shares, financial instruments and businesses; and
- change the nature of the Group's activities.

In each case, subject to the stipulated de minimis amounts and customary exceptions for financing of this type.

The Senior Credit Agreement also contains positive undertakings, including maintaining insurance policies, complying with applicable laws and ensuring that the borrowings under the Senior Credit Agreement rank at least pari passu with the Company's other unsecured and unsubordinated obligations. The Senior Credit Agreement also requires compliance with a financial ratio that limits the amount of financial indebtedness that may be incurred by members of the Group. Specifically, the Group must maintain a leverage ratio (total net debt/adjusted EBITDA, calculated in accordance with the terms of the Senior Credit Agreement on the basis of the Company's consolidated financial statements) of no more than 3.0:1 until the maturity of the Senior Credit Agreement. This ratio is tested at the end of each half-year, beginning with the first half-year following the Company's initial public offering. In addition, the financial indebtedness that may be incurred by the Company's principal subsidiaries is limited to (i) financial indebtedness incurred with another member of the Group, (ii) short-term financial indebtedness incurred in the ordinary course of business and (iii) any other financial indebtedness whose outstanding principal amount does not at any time exceed the greater of 15 million euros and an amount equal to 15% of adjusted EBITDA.

Voluntary early repayment

The Senior Credit Agreement allows for voluntary early repayments subject to notice and a minimum amount.

Mandatory early repayment

The Senior Credit Agreement provides for early repayment and/or cancellation in the event of a change of control. Each Lender has the right to request the cancellation of its available commitments and the repayment of the advances it has made available under the Senior Credit Agreement within 30 calendar days from the date on which the Company notifies the credit agent of the change of control. Its available commitments will then be cancelled at the end of a period of five working days after the request for cancellation, and its advances will be repaid 60 calendar days after the Company notifies the change of control to the credit agent.

A change of control would occur in the event that (i) the Company ceases to hold, directly or indirectly, 100% of the capital or voting rights of EXOSENS International or (ii) a person or group of persons (other than (a) HLD Europe and other funds and/or vehicles and/or companies advised by and/or managed by (A) HLD Associés Europe and/or (B) an affiliate of HLD Associés Europe and (b) the management of the Group, acting in concert (within the meaning of Article L. 233-10 of the French Commercial Code), acquires control (within the meaning of Article L. 233-3 of the French Commercial Code) of the Company.

Events of default

The Senior Credit Agreement provides for a number of events of default customary for financing of this type, including payment defaults, non-compliance with the financial covenant or any other undertaking, cross-defaults, insolvency proceedings and disputes having a material adverse effect.

1.4.2 The Group's consolidated cash flows

Net cash from/(used in) operating activities

The table below shows the Group's cash flows from operating activities for the first half of 2026 and the first half of 2025.

(in € millions)	1st half 2026	1st half 2025 restated
Profit/(loss)	15.3	29.6
Adjustments:		
• Net finance income/(expense)	6.0	8.3
• Income tax	9.9	11.1
• Depreciation/amortisation of intangible assets and property, plant and equipment	46.1	19.1
• Other income and expenses	3.9	2.0
Income tax received (paid)	-6.2	-3.5
Change in working capital, net of impairment	-11.2	-16.0
NET CASH FROM/(USED IN) OPERATING ACTIVITIES	**63.9**	**50.8**

The Group's cash flows from operating activities amounted to 63.9 million euros in the first half of 2026 compared with 50.8 million euros in the first half of 2025.

This change was mainly attributable to strong growth in the Group's activities, which notably generated an increase of +12.9 million euros in adjusted EBITDA.

The change in working capital requirements was notably affected by higher inventories associated with business growth and preparation for second-half deliveries, together with a high level of trade receivables reflecting growth in the first half of the year.

Net cash from/(used in) investing activities

The table below shows the Group's cash flows from investing activities for the first half of 2026 and the first half of 2025.

(in € millions)	1st half 2026	1st half 2025 restated
Net capital expenditure	-35.4	-21.2
Acquisitions of equity interests, net of cash acquired	-3.9	-35.8
Investment grants received	0.0	0.0
NET CASH FROM/(USED IN) INVESTING ACTIVITIES	**-39.3**	**-57.0**

Net cash flows from the Group's investments mainly correspond to intangible and tangible investments, as well as acquisitions.

The Group's cash flows from investing activities amounted to -39.3 million euros in the first half of 2026 compared with -57.0 million euros in the first half of 2025.

The change of -17.7 million euros in net cash used in investing activities mainly reflected:

- the absence of any significant acquisitions during the first half of 2026 (acquisition of Noxant for 36.1 million euros net of cash acquired as at 30 June 2025);
- an increase in the Group's capital expenditure and capitalised research and development costs to support strong business growth, with net investment in property, plant and equipment and intangible assets increasing from 21.2 million euros in the first half of 2025 to 35.4 million euros in the first half of 2026.

Net cash from/(used in) financing activities

The following table shows the Group's cash flows from financing activities for the first half of 2026 and the first half of 2025.

(in € millions)	1st half 2026	1st half 2025 restated
Increases and decreases in share capital	0.0	0.0
Treasury share purchases and sales	-1.0	-0.2
Dividends paid	-15.2	-5.1
Changes in financial liabilities and IFRS 16 lease liabilities	0.0	-2.8
Interest paid (including on leases pursuant to IFRS 16)	-5.8	-6.4
Other	-2.8	1.3
NET CASH FROM/(USED IN) FINANCING ACTIVITIES	**-24.8**	**-13.1**

The Group's cash flows from financing activities amounted to -24.8 million euros in the first half of 2026 compared with -13.1 million euros in the first half of 2025.

The main cash flows from financing activities in the first half of 2026 mainly comprised:

- The payment of dividends amounting to 15.2 million euros; and
- interest payments totalling 5.8 million euros (including IFRS 16 leases).

1.4.3 Free cash flow

The following table presents the Group's free cash flow for the first half of 2026 and the first half of 2025.

In € millions	1st half 2026	1st half 2025 restated
ADJUSTED EBITDA	**83.6**	**70.6**
Capitalised R&D costs	(9.2)	(6.1)
ADJUSTED EBITDA AFTER CAPITALISED R&D COSTS	**74.5**	**64.5**
Change in working capital	(11.2)	(16.0)
Income tax paid	(6.2)	(3.5)
Maintenance capital expenditure	(4.7)	(5.3)
Other	(2.3)	(0.4)
FREE CASH FLOW BEFORE GROWTH CAPITAL EXPENDITURE	**50.1**	**39.4**
Growth capital expenditure	(18.7)	(9.4)
FREE CASH FLOW AFTER GROWTH CAPITAL EXPENDITURE	**31.4**	**30.0**

Exosens generated free cash flow of 31.4 million euros in the first half of 2026, compared with 30.0 million euros in the first half of 2025. The strong increase in the Group's adjusted EBITDA was partly offset by higher growth capital expenditure related to the continued implementation of its production capacity expansion plan. The Group also maintained disciplined working capital management despite strong revenue growth, resulting in an improvement in its working capital requirement measured in days of sales.

1.4.4 Financial debt

The table below shows the gross debt/cash/net debt/leverage ratio indicators:

(in € millions)	30 June 2026	31 December 2025
Gross debt	269.5	266.4
Cash and cash equivalents	68.8	68.6
Net debt	199.8	197.7
Pro forma adjusted EBITDA	166.7	156.1
Leverage ratio*	1.2	1.3

* *The leverage ratio is calculated as net debt/pro forma adjusted EBITDA, as defined in the Group's senior credit agreements. Pro forma adjusted EBITDA includes the contribution from acquisitions completed during the previous 12 months as if the acquired businesses had been owned throughout that period (unaudited).*

As at 30 June 2026 and 31 December 2025, the Group had total gross financial debt of 269.5 million euros and 266.4 million euros respectively, and net debt of 199.8 million euros and 197.7 million euros respectively.

For the six months ended 30 June 2026, the cost of net debt amounted to 6.3 million euros, compared with 6.6 million euros for the six months ended 30 June 2025 restated.

1.5 RELATED-PARTY TRANSACTIONS

Group transactions with related parties mainly comprise:

- compensation and benefits allocated to management bodies;
- commercial and financial transactions with the Group's unconsolidated subsidiaries and associates: the Group has no material relationships with its unconsolidated subsidiaries and no associates within its consolidation scope.

Related-party transactions are conducted on an arm's-length basis.

There were no significant changes in the nature of transactions between the Group and related parties during the first half of 2026 compared with 31 December 2025.

1.6 MAIN RISKS AND UNCERTAINTIES

The main risks and uncertainties that the Group could face in the remaining six months of the 2026 financial year are identical to those presented in Chapter 4 "Risk factors and risk management systems" of the 2025 Universal Registration Document filed with the Autorité des marchés financiers on 9 March 2026.

1.7 2026 OUTLOOK

Building on sustained commercial momentum, particularly in the Defense and Surveillance markets, and strong operational execution, Exosens remains fully on track to deliver on its 2026 guidance and now expects revenue and adjusted EBITDA to be towards the upper end of their respective ranges:

- Revenue in the range of €520 million to €540 million;
- Adjusted EBITDA in the range of €168 million to €178 million.

In addition, the Group intends to continue implementing its investment plan aimed at expanding production capacity by 40% by 2027, both in Europe and the United States, to meet strong demand, while continuing its efforts to improve productivity. In this context, the Group expects capital expenditure to represent around 9% of 2026 revenue (excluding capitalized R&D expenses, expected at around 3% of revenue).

02 CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS AT 30 JUNE 2026

2.1 GROUP CONSOLIDATED FINANCIAL STATEMENTS

2.1.1 Consolidated financial statements as at 30 June 2026

Consolidated balance sheet

(in € thousands)	Note	30 June 2026	31 December 2025
Goodwill	15	233,441	233,332
Intangible assets	16	197,337	225,799
Property, plant and equipment	17	128,600	113,073
Right-of-use assets	18	15,741	15,032
Investments in equity-accounted companies and other investments	19	8,459	3,840
Non-current financial assets and other non-current assets		653	625
Deferred tax assets	13	5,012	6,948
NON-CURRENT ASSETS		**589,242**	**598,650**
Inventories	20	123,257	105,088
Trade receivables	21	76,011	73,125
Derivative financial instruments	25	848	146
Current financial assets and other current assets	22	36,821	33,252
Cash and cash equivalents	23	68,808	68,618
CURRENT ASSETS		**305,745**	**280,229**
TOTAL ASSETS		**894,987**	**878,878**
Share capital	24	21,648	21,648
Share premiums	24	346,763	346,763
Reserves		82,472	77,242
EQUITY		**450,884**	**445,654**
Non-current loans and borrowings	25	251,440	249,281
Non-current lease liabilities	25	12,781	13,645
Provisions for post-employment benefit obligations	27	7,750	7,864
Non-current provisions and other non-current liabilities	26	11,969	14,175
Deferred tax liabilities	13	30,204	34,559
NON-CURRENT LIABILITIES		**314,144**	**319,524**
Current loans and borrowings	25	281	493
Current lease liabilities	25	4,970	2,971
Derivative financial instruments	25	0	76
Trade payables	28	35,633	31,196
Current provisions and other current liabilities	26	89,075	78,966
CURRENT LIABILITIES		**129,959**	**113,701**
TOTAL EQUITY AND LIABILITIES		**894,987**	**878,878**

Notes 1 to 33 are an integral part of the condensed consolidated interim financial statements.

Consolidated income statement

(in € thousands)	Note	30 June 2026	30 June 2025 restated
Revenue	6	253,067	219,478
Cost of sales		-57,706	-48,919
Other purchases and external expenses	7	-39,547	-35,003
Taxes		-1,742	-1,056
Employee benefit expense	8	-77,014	-67,629
Other operating income	9	2,328	1,567
Other operating expenses	9	-1,916	-871
Depreciation, amortisation, impairment and provision charges, net of reversals	10	-46,244	-18,505
CURRENT OPERATING PROFIT/(LOSS)		**31,226**	**49,061**
Other income	11	21	8
Other expenses	11	0	-48
OPERATING PROFIT/(LOSS)		**31,246**	**49,021**
Cost of net debt		-6,330	-6,644
Net gains/(losses) on derivative instruments		483	-2,945
Other		-191	1,267
Net finance income/(expense)	12	-6,038	-8,322
PROFIT/(LOSS) BEFORE TAX		**25,208**	**40,699**
Income tax	13	-9,869	-11,087
PROFIT/(LOSS) FROM CONTINUING OPERATIONS ATTRIBUTABLE TO OWNERS OF THE PARENT		**15,340**	**29,612**
Profit/(loss) from discontinued operations attributable to owners of the parent	4	0	-1,703
PROFIT/(LOSS) ATTRIBUTABLE TO OWNERS OF THE PARENT		**15,340**	**27,909**
EARNINGS PER SHARE			
Basic	14	0.30	0.55
Diluted	14	0.30	0.55

The 2025 figures have been restated in accordance with IFRS 5. Discontinued operations have been reclassified and presented separately in the specific line items for discontinued operations in the consolidated income statement and statement of cash flows (see Note 4, "Discontinued operations").

Notes 1 to 33 are an integral part of the condensed consolidated interim financial statements.

Consolidated statement of comprehensive income

(in € thousands)	30 June 2026	30 June 2025 restated
PROFIT/(LOSS)	**15,340**	**27,909**
Actuarial gains/(losses) on post-employment benefit obligations and similar obligations, before tax	0	20
Deferred tax on post-employment benefit obligations and similar obligations	0	-5
Items of other comprehensive income that will not be reclassified subsequently to profit or loss	***0***	***15***
Fair value gains/(losses) on hedging instruments, before tax	878	-479
Deferred tax on fair value gains/(losses) on hedging instruments	-219	120
Translation adjustments[(1)]	2,173	-6,336
Items of other comprehensive income that may be reclassified subsequently to profit or loss	***2,832***	***-6,696***
OTHER COMPREHENSIVE INCOME	**2,832**	**-6,681**
TOTAL COMPREHENSIVE INCOME	**18,171**	**21,228**
Attributable to owners of the parent	18,171	21,228

(1) The line "translation adjustments" corresponds to exchange differences relating to loans granted to subsidiaries denominated in foreign currency and forming part of the net investment in these subsidiaries. In accordance with IAS 21, these exchange differences are recognised in other comprehensive income and subsequently reclassified to profit or loss on disposal of the net investment.

Notes 1 to 33 are an integral part of the condensed consolidated interim financial statements.

Consolidated statement of cash flows

(in € thousands)	Note	30 June 2026	30 June 2025 restated
Profit/(loss)		15,340	29,612
Adjustments:			
• Finance income and expenses with an impact on cash	12	5,433	5,289
• Finance income and expenses with no impact on cash	12	606	3,084
• Income tax	13	9,869	11,087
• Depreciation, amortisation, impairment and provision charges, net of reversals	10	46,143	19,138
• Other income and expenses(1)		3,911	2,033
Income tax received (paid)		-6,170	-3,496
Change in working capital, net of impairment		-11,205	-15,982
NET CASH FROM/(USED IN) OPERATING ACTIVITIES		**63,926**	**50,764**
Purchases of intangible assets and property, plant and equipment	16/17	-32,502	-20,751
Proceeds on disposal of intangible assets and PP&E		0	0
Acquisitions of equity investments, net of cash acquired(2)		-3,899	-35,766
Proceeds on disposal of equity investments, net of cash divested		0	0
Investment grants received		0	0
Cash flows relating to other financial assets	3	-2,866	-475
NET CASH FROM/(USED IN) INVESTING ACTIVITIES		**-39,267**	**-56,992**
Increases and decreases in share capital		0	0
Cost of share capital increases		0	0
Treasury share purchases and sales		-979	-177
Dividends paid		-15,204	-5,078
Refinancing non-current borrowings	25	0	0
Repayments of non-current borrowings	25	-73	0
Refinancing of current borrowings	25	2,200	0
Repayment of current borrowings	25	-473	-1,494
Finance expenses paid in relation to borrowings	12	-5,172	-6,013
Repayment of IFRS 16 lease liabilities	25	-1,616	-1,290
Finance expenses paid in relation to IFRS 16 lease liabilities		-655	-404
Finance income received in relation to derivatives		-93	-162
Finance income received on investments		111	1,379
Debt issuance costs	25	-350	0
Early repayment fees on borrowings		0	0
Other(3)		-2,503	99
NET CASH FROM/(USED IN) FINANCING ACTIVITIES		**-24,808**	**-13,140**
EFFECT OF EXCHANGE RATE CHANGES		**441**	**-735**
Increase/(Decrease) in cash and cash equivalents		292	-20,103
Net cash from/(used in) discontinued operations		0	-6,701
Opening cash and cash equivalents	23	68,515	115,629
Closing cash and cash equivalents	23	68,807	88,825

(1) *For the six months ended 30 June 2026, "Other income and expenses" mainly comprised 3.2 million euros relating to the impact of IFRS 2. For the six months ended 30 June 2025, "Other income and expenses" mainly comprised 0.9 million euros relating to the impact of IFRS 2 and 0.4 million euros of income from the release of grants (non-cash).*

(2) *2026 financial year: consisting mainly of the acquisition of Emberion shares for 2.5 million euros and the exercise of a call option on NVLS for 1.4 million euros. 2025 financial year: consisting mainly of the acquisition of Noxant shares, net of cash acquired.*

(3) *As at 30 June 2026, the "Other" line item mainly comprised cash advances made to Emberion following its acquisition to finance its operations.*

Notes 1 to 33 are an integral part of the condensed consolidated interim financial statements.

Consolidated statement of changes in equity

				Reserves			
(in € thousands)	Share capital (Note 24)	Share premiums (Note 24)	Treasury shares	Translation adjustments	Other reserves	Retained earnings	Total
AS AT 1 JANUARY 2025	**21,583**	**342,537**	**-**	**1,965**	**-10,379**	**56,895**	**412,601**
Changes in cash flow hedges	-	-		-	52	-	52
Actuarial gain/(loss) on post-employment benefits	-	-		-	-399	-	-399
Translation adjustments	-	-		-5,824	-	-	-5,824
Other comprehensive income	**-**	**-**		**-5,824**	**-346**	**-**	**-6,170**
Profit/(loss) for the period	-	-		-	-	42,715	42,715
Total comprehensive income for the period	**-**	**-**		**-5,824**	**-346**	**42,715**	**36,545**
Capital increase	66	4,227		-	-	-	4,292
Capital reduction	-	-		-	-	-	-
Adjustment to the number and the value of treasury shares [(2)]			-8,786				
Dividend distribution	-			-	-	-5,078	-5,078
Other [(3)]	-	-		-	6,081	-	6,081
AS AT 31 DECEMBER 2025	**21,648**	**346,763**	**-8,786**	**-3,859**	**-4,644**	**94,532**	**445,654**
AS AT 1 JANUARY 2026	**21,648**	**346,763**	**-8,786**	**-3,859**	**-4,644**	**94,532**	**445,654**
Changes in cash flow hedges	-	-		-	656	-	656
Actuarial gain/(loss) on post-employment benefits	-	-		-	-	-	-
Translation adjustments	-	-		2,173	-	-	2,173
Other comprehensive income[(1)]	**-**	**-**		**2,173**	**656**	**-**	**2,829**
Profit/(loss) for the period	-	-		-	-	15,340	15,340
Total comprehensive income for the period	**-**	**-**		**2,173**	**656**	**15,340**	**18,169**
Capital increase	-	-		-	-	-	-
Capital reduction	-	-		-	-	-	-
Distribution of dividends[(2)]	-			-	**-**	**-15,204**	-15,204
Other[(3)]	-	-		-	2,265	-	2,265
AS AT 30 JUNE 2026	**21,648**	**346,763**	**-8,786**	**-1,686**	**-1,723**	**94,667**	**450,884**

(1) The "translation adjustments" line corresponds to exchange differences relating to loans granted to subsidiaries denominated in foreign currency and forming part of the net investment in these subsidiaries. In accordance with IAS 21, these exchange differences are recognised in other comprehensive income (recyclable OCI) and then reclassified to profit or loss when the net investment is disposed of.

(2) See Note 1.3.3.

(3) This item mainly comprises the corresponding entry for the IFRS 2 impact, amounting to 3,243 thousand euros, and the elimination of treasury shares, with an impact of -979 thousand euros.

2.1.2 Notes to the consolidated financial statements

Detailed contents of the notes

NOTE 1. General information

EXOSENS ("the Company") and its subsidiaries (together, "the Group" or "the EXOSENS Group") form a high-tech group specialising in the innovation, development, manufacture and sale of amplification, detection and imaging technologies. EXOSENS offers its customers detectors and imaging solutions such as image intensifier tubes, digital cameras and ion, electron, neutron and gamma-ray detectors. EXOSENS responds to complex issues in extremely demanding environments by offering tailor-made solutions to its customers in the defence and surveillance, life sciences, nuclear and industrial control sectors. Through sustained, ongoing investment in R&D, the Group is internationally recognised as a major innovator in optoelectronics. It has 13 production sites in Europe and North America and more than 2,000 employees. The EXOSENS Group also manufactures components for high-tech digital cameras and scientific detectors used, for example, in space exploration or the nuclear industry. The Group is present in more than 70 countries.

EXOSENS is a public limited company (*société anonyme*, SA) governed by French law. Its registered office is located at Domaine de Pelus, Axis Business Park, Bloc E, 18 avenue de Pythagore, Mérignac, France. The Company is listed on the Paris Stock Exchange (Euronext) and is part of the SBF 120 stock index.

On 27 July 2026, the Board of Directors authorised for issue the condensed consolidated interim financial statements for the six-month period from 1 January 2026 to 30 June 2026. All amounts are presented in thousands of euros, and all values are rounded to the nearest thousand unless otherwise stated. Numbers may not sum precisely due to rounding.

NOTE 2. Preparation procedures

2.1 Statement of compliance

The Group's condensed consolidated interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting. They do not include all the disclosures required in annual financial statements and should be read in conjunction with the Group's consolidated financial statements for the year ended 31 December 2025, which were prepared in accordance with IFRS as adopted by the European Union and mandatory at the reporting date.

2.2 Accounting principles

The accounting principles used to prepare these condensed consolidated interim financial statements are consistent with those used by the Group to prepare its consolidated financial statements for the year ended 31 December 2025.

2.3 New standards, amendments and interpretations adopted by the European Union and mandatory for financial years beginning on or after 1 January 2026

The standards, amendments and interpretations that are mandatory and applicable from 1 January 2026 have no significant impact on the Group's consolidated financial statements. They mainly concern:

- Annual Improvements to IFRS Accounting Standards – Volume 11 (including amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7).

2.4 New standards, amendments and interpretations issued but not mandatory as at 1 January 2026

The Group has not early-adopted any of the following new standards and interpretations that could concern it but which were not mandatory as at 1 January 2026:

- IFRS 19, Subsidiaries without Public Accountability: Disclosures;
- IFRS 18, Presentation and Disclosure in Financial Statements.

A study of the impacts and practical consequences of the application of these amendments to standards, excluding IFRS 18, is underway. The expected impact of these amendments is not material.

IFRS 18, subject to its adoption by the European Union, will be applicable to all financial years beginning on or after 1 January 2027 with retrospective application. The Group is currently assessing the impact of this new standard on its performance indicators, the presentation of its consolidated financial statements and its accounting information systems.

2.5 Climate risk

To the best of its knowledge, the Group takes climate risks into account in its reporting-date assumptions and reflects their potential effects in its financial statements.

The process implemented and described in the consolidated financial statements for the year ended 31 December 2025 in Note 2.4 remains unchanged.

2.6 Key assumptions and main sources of estimates

The preparation of these condensed consolidated interim financial statements requires management to make assumptions and estimates in determining the carrying amounts of assets and liabilities at the reporting date and income and expenses for the period. Actual results may differ from those estimates.

The main sources of estimation uncertainty and management judgement relate to the capitalisation of development costs, impairment of non-financial assets, employee benefits, recognition and measurement of deferred taxes, goodwill, intangible assets acquired in business combinations and their estimated useful lives, determination of the enforceable period of leases, provisions, litigation and recognition of revenue over time.

2.7 Specific recognition and measurement principles applied by the Group in interim financial reporting

Seasonality of activity

The Group's revenue is affected by the seasonal nature of the products sold to its customers. Order levels are typically higher at the end of the year, particularly for Amplification products, which are primarily related to the defence sector, which responds, in particular, to budgetary constraints. The Group's revenue in the first half of the financial year is generally lower than in the second half; therefore, it cannot be extrapolated to the entire financial year.

No adjustment has been made for seasonal factors in the Group's condensed consolidated interim financial statements.

Income and expenses from ordinary activities that are received or incurred seasonally, cyclically or occasionally are recognised using the same principles as at the annual reporting date. They are neither anticipated nor deferred at the half-year reporting date. Expenses and income invoiced annually, such as patent and licence royalties, are recognised on the basis of an annual estimate prorated for the period elapsed.

Risks arising during the period are provided for in the period's accounts. A provision is recognised in full for identified losses on completion of onerous contracts.

Assessment of the tax burden

The corporate income tax expense for the first half of the year is based on the best estimate of the average annual tax rate expected for the full year. This rate may be adjusted for the tax implications of unusual items during the period.

Retirement commitments

The commitment for post-employment employee benefits and the associated provision are valued on the basis of the latest actuarial valuations available at the closing date of the previous financial year. A review of actuarial assumptions is carried out for the main employee benefit plans. The main assumptions are adjusted if developments during the period are considered material.

NOTE 3. Changes in consolidation scope and major events

3.1 Change in consolidation scope

In accordance with IFRS 10, the Group's financial statements include all entities over which the Group exercises exclusive control, meaning, when the Group has the power to direct an entity's financial and operating policies in order to derive benefits from it. Control is presumed to exist when the Group holds more than half of the voting rights, directly or indirectly, unless proven otherwise. Newly acquired or created entities are included in the scope of consolidation from the date on which control is effectively transferred to the Group. Similarly, entities that are sold are excluded from the scope from the date of loss of control.

Transactions during the year 2026

Acquisition of Emberion

On 24 April 2026, the EXOSENS Group acquired 100% of the shares in Emberion, a company incorporated under Finnish law and located at Metsänneidonkuja 8, 02130 Espoo. Emberion specialises in the manufacture of next-generation infrared sensors based on quantum dot technology. This acquisition strengthens EXOSENS' position in the infrared imaging market.

Emberion was not consolidated as at 30 June 2026. Accordingly, the acquisition cost of the shares is recognised as an asset in the statement of financial position under "Investments in equity-accounted companies and other investments". The company will enter the consolidation scope in the second half of 2026. Its contribution would not have had a material impact on the Group's consolidated financial statements.

Adelphi Technology

On 13 May 2026, the EXOSENS Group acquired 29.99% of the capital of Adelphi Technology Inc., for a total investment of 2,303 thousand euros. Adelphi Technology is a US company specialising in the design and manufacture of compact neutron generators. This investment supports the development of the Group's Neutronis programme.

Based on the rights attached to its interest, the Group has significant influence over Adelphi Technology but does not control it as defined in IFRS 10. Accordingly, the investment has been accounted for using the equity method in accordance with IAS 28 since the acquisition date.

As at 30 June 2026, the carrying amount of the investment was 2,303 thousand euros, corresponding to its acquisition price.

3.2 Major Events

Contract with ACTinBlack for the supply of 5G image intensifier tubes

On 12 January 2026, EXOSENS announced that ACTinBlack Group, one of Europe's leading manufacturers of advanced night vision systems, had ordered more than 7,000 5G image intensifier tubes for use by European special forces. This contract was secured only a few months after the official unveiling of 5G, EXOSENS' new technology, underscoring its rapid market adoption. The tubes are scheduled for delivery in 2027 and 2028. They will be integrated into night vision goggles intended for European special forces end users.

US Army BiNOD contract for the supply of advanced night vision solutions

On 2 March 2026, the Group was awarded a US Army BiNOD contract with a maximum value of 352.6 million US dollars. This Indefinite Delivery/Indefinite Quantity (IDIQ) contract covers the development, production and testing of the US Army's BiNOD (Binocular Night Observation Device) binocular night vision devices until 27 February 2033.

The award marks a major milestone in EXOSENS' expansion in the United States, where the Group's scalable industrial footprint supports its development in the world's most demanding market for night vision devices.

Doubling of cooled infrared camera production capacity

The Group plans to double its production capacity for cooled infrared cameras during 2026 in response to accelerating global demand for advanced digital imaging solutions, particularly in long-range surveillance and counter-drone applications.

Manufactured in France, EXOSENS' high-performance cooled infrared imaging solutions are designed for seamless integration into a wide range of platforms, such as gimbals, turrets, surveillance payloads and protection systems deployed on drones, robots and vehicles. They are increasingly being adopted by a broad range of industry players, from major defence contractors to leading OEMs and autonomous systems developers.

Unification of the Group's brands under the single EXOSENS brand

During the first half of 2026, the Group began gradually consolidating its entire product portfolio under the single EXOSENS brand. This strategic initiative builds on the Group's growth and the integration of the companies acquired in recent years. In this context, the Photonis, Telops and Xenics brands were fully impaired (Note 16, "Intangible assets", and Note 10, "Depreciation, amortisation, impairment and provision charges"). This change is intended to strengthen the consistency, visibility and recognition of the EXOSENS brand among its customers and partners.

New financing from the European Investment Bank (EIB)

On 24 June 2026, the Group entered into a 140 million euro financing agreement with the European Investment Bank (EIB), backed by the InvestEU programme. This financing facility is intended to support the Group's research, development and innovation activities, as well as selected industrial investments serving the European defence, surveillance and industrial markets. This transaction enables the Group to diversify its sources of financing and support the implementation of its growth and innovation strategy.

Contract to supply 17,000 image intensifier tubes to the Czech Armed Forces

On 29 June 2026, EXOSENS announced that BROLIS had ordered 17,000 image intensifier tubes for the Czech Armed Forces, to be delivered by 2032. Under the agreement, EXOSENS will deliver its high-performance image intensifier tubes to BROLIS through 2032, supporting the modernisation of the Czech Armed Forces' night vision capabilities while providing the Group with long-term revenue visibility.

This programme represents the largest procurement of image intensifier tubes ever undertaken by the Czech Republic, demonstrating the field-proven operational performance, reliability and quality of EXOSENS' advanced night vision technologies. It further strengthens the Group's position as a trusted, ITAR-free supplier of mission-critical night vision components to NATO armed forces and leading defence system integrators.

NOTE 4. Discontinued operations

On 10 October 2025, the Group signed an asset purchase agreement for the sale of its entire Microwave Amplification (MA) business unit, which specialises in microwave amplifiers for the US defence market. The transaction was completed on 31 December 2025.

This sale forms part of the Group's strategy of focusing its resources on higher value-added activities with superior growth and profitability prospects. The MA business, which is subject to a Special Security Agreement and governed by a specific structure, constitutes a separate business line with no significant synergies with the rest of the Group. It experienced a continuous decline in revenue until 2024, and its operations resulted in significant cash burn in recent years, justifying the decision to sell.

In accordance with IFRS 5, this business was reclassified as a discontinued operation. Its contribution to the Group's income statement and the related cash flows are now presented separately under the specific line items for discontinued operations in the consolidated income statement and statement of cash flows for 2025. To ensure comparability, the figures for the first half of 2025 have been restated on the same basis.

In accordance with IFRS 5, the profit or loss for the period is presented under profit/(loss) from discontinued operations:

INCOME STATEMENT OF DISCONTINUED OPERATIONS	30 June 2026	30 June 2025 restated
Revenue	0	5,038
OPERATING PROFIT/(LOSS)	**0**	**-2,304**
Net finance income/(expense)	0	-5
Income tax	0	606
PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS	**0**	**-1,703**
Gain/(loss) on disposal of the MA business, net of tax	0	
PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS	**0**	**-1,703**

The MA business's contribution to cash flows is presented as follows:

Contribution to cash flows from discontinued operations *(in € thousands)*	30 June 2026	30 June 2025 restated
Net operating cash flow from discontinued operations	0	-6,105
Net cash flow from investing activities related to discontinued operations	0	-307
Net cash flow from financing activities related to discontinued operations	0	-289
Exchange rate fluctuations related to discontinued operations	0	0
CHANGE IN CASH AND CASH EQUIVALENTS FROM DISCONTINUED OPERATIONS	**0**	**-6,701**

NOTE 5. Segment reporting

Accounting policy

The operating segments are reported in a manner consistent with the internal reporting provided to Group Management.

The Chief Executive Officer regularly reviews the adjusted gross margin of each segment to assess its performance. He has therefore been identified as the Group's chief operating decision-maker.

Segment information is presented for the following two operating segments:

- Amplification, comprising systems that use electron or electromagnetic-wave amplification to produce an image or a power source;
- Detection & Imaging, comprising systems that detect signals (optical or electronic) or generate images across different wavelength bands of the optical spectrum (from ultraviolet to infrared).

The Group uses key financial and non-financial measures to analyse the performance of its business. The key performance indicators used include revenue, adjusted gross margin and adjusted EBITDA.

Adjusted gross margin, presented below by segment, is the difference between the selling price and the cost of products and services (including employee costs). The detailed definition of this measure and its reconciliation to operating profit are presented in a table later in this note.

The Group defines adjusted EBITDA as operating profit adjusted to exclude (i) depreciation, amortisation and impairment of non-current assets, net of reversals; (ii) non-recurring income and expenses presented in the consolidated income statement under "Other income" and "Other expenses"; and (iii) the effects of items that do not reflect core operating performance, particularly business restructuring and adaptation costs, acquisition and external growth costs and expenses associated with share-based payments (IFRS 2).

Adjusted gross margin and adjusted EBITDA are not standard accounting measures with generally accepted definitions. They should not be considered substitutes for operating profit, net profit or cash flow from operating activities or indicators of liquidity. Other companies may calculate adjusted gross margin and adjusted EBITDA using definitions different from those used by the Group.

	30 June 2026			
(in € millions)	Amplification	Detection & Imaging	Other, eliminations and unallocated	Total
Sales	176.3	77.4	-0.6	253.1
Contribution (% of total sales)	69.7%	30.6%	-0.3%	
Adjusted gross margin	92.6	37.2	0.1	129.9
As a percentage of sales	52.5%	48.1%	-9.7%	51.3%
Adjusted EBITDA	-	-	-	83.6
As a percentage of sales				33.0%

	30 June 2025 restated			
(in € millions)	Amplification	Detection & Imaging	Other, eliminations and unallocated	Total
Sales	157.9	62.3	-0.7	219.5
Contribution (% of total sales)	71.9%	28.4%	-0.3%	
Adjusted gross margin	81.2	30.3	-0.1	111.5
As a percentage of sales	51.5%	48.7%	-%	50.8%
Adjusted EBITDA	-	-	-	70.6
As a percentage of sales				32.2%

Revenue reported under "Other, eliminations and unallocated items" mainly represents the elimination of inter-segment sales.

Unallocated adjusted gross margin includes the profit/(loss) from Corporate activities not allocated to the segments and the elimination of inter-segment flows.

Reconciliation with the consolidated financial statements – Adjusted EBITDA

	30 June 2026	30 June 2025 restated
ADJUSTED EBITDA	**83.6**	**70.6**
Depreciation, amortisation and impairment of non-current assets (including IFRS 16) (Note 10)	-47.9	-17.1
Other income and expenses (Note 11)	0.0	0.0
Other*	-4.6	-4.5
OPERATING PROFIT/(LOSS)	**31.2**	**49.0**

* *The "Other" line mainly includes expenses associated with share-based payments (IFRS 2) amounting to -3.0 million euros and non-recurring costs of -1.6 million euros relating mainly to external acquisition activities.*

Reconciliation with the consolidated financial statements – Adjusted Gross Margin

Operating profit is obtained after deduction of the following operating expenses:

- **cost of sales:** production cost of products and services (including employee costs);
- **research and development costs:** expenditure on innovation, research and development;
- **selling, general and administrative expenses:** costs of support functions and day-to-day management;
- **other operating income and expenses:** specific, non-recurring items.

These elements reflect the Group's cost structure and reconcile the gross margin to the operating profit.

(in € millions)	30 June 2026	30 June 2025 restated
REVENUE	**253.1**	**219.5**
Cost of sales*	-123.2	-108.0
ADJUSTED GROSS MARGIN	**129.9**	**111.5**
Research and development costs*	-10.4	-13.3
Sales, general and administrative costs*	-88.3	-48.3
Other operating income and expenses	0.0	-0.8
CURRENT OPERATING PROFIT/(LOSS)	**31.2**	**49.1**

* *The figures presented in the R&D and selling expenses lines are derived from internal management reporting and do not constitute audited IFRS measures. They are therefore not directly comparable with similar indicators shown in the financial statements.*

Non-current assets break down by geographic area as follows:

	30 June 2026				31 December 2025			
(in € millions)	France	Europe excluding France	North America	Other	France	Europe excluding France	North America	Other
Goodwill, intangible assets, property, plant and equipment and right-of-use assets	389.1	121.9	50.8	13.3	400.7	121.1	52.4	13.0

NOTE 6. Revenue

Group revenue breaks down as follows:

(in € thousands)	30 June 2026	%	30 June 2025 restated	%
Sales of goods	247,892	98.0%	216,083	98.5%
Sales of services & licence fees	5,175	2.0%	3,395	1.5%
TOTAL REVENUE	**253,067**	**100.0%**	**219,478**	**100.0%**

The Group's revenue by geographical area is broken down as follows:

(in € thousands)	30 June 2026	%	30 June 2025 restated	%
Europe	195,631	77.3%	170,875	77.9%
Of which Greece	*97,042*	*38.3%*	*88,572*	*40.4%*
Of which France	*11,465*	*4.5%*	*14,337*	*6.5%*
North America	18,957	7.5%	14,109	6.4%
Of which United States	*16,800*	*6.6%*	*11,822*	*5.4%*
Asia	35,770	14.1%	32,882	15.0%
Oceania	1,506	0.6%	1,378	0.6%
Africa	94	-%	128	0.1%
Other	1,110	0.4%	106	-%
TOTAL REVENUE	**253,067**	**100.0%**	**219,478**	**100.0%**

Sales recognised at a point in time when control of the goods or services is transferred to the customer represented 99.0% of Group sales in the six months ended 30 June 2026 (98.3% in the six months ended 30 June 2025 restated) and totalled 250.4 million euros (215.8 million euros in the six months ended 30 June 2025 restated). In 2026, sales recognised over time as performance obligations were satisfied amounted to 2.6 million euros, representing 1.0% of total sales for the period (3.7 million euros and 1.7%, respectively, in the six months ended 30 June 2025 restated).

The Group estimates that around 85% of its revenue comes from the sale of dual-use goods. Dual-use goods are products, software and technologies which can be used for both civil and military applications.

NOTE 7. Other purchases and external expenses

(in € thousands)	30 June 2026	30 June 2025 restated
Temporary employees	-12,287	-10,600
Professional fees	-7,441	-7,258
Travel and entertainment	-2,223	-1,879
Subcontracting	-3,713	-2,552
Rent	-1,008	-996
Maintenance	-5,821	-6,744
Advertising, publications, public relations	-1,254	-1,022
Insurance premiums	-1,215	-968
Transport of goods and collective passenger transport	-803	-553
Postal and telecommunication costs	-487	-475
Banking and related services	-678	-176
Other services – miscellaneous	-825	-712
Studies and research	-730	-427
Other (sundry external services, property management expenses, rental)	-1,060	-642
OTHER PURCHASES AND EXTERNAL EXPENSES	**-39,547**	**-35,003**

For the six months ended 30 June 2026, the "Other purchases and external expenses" line was -39,547 thousand euros (-35,003 thousand euros for the six months ended 30 June 2025 restated). This increase mainly reflected increases of 1,687 thousand euros in temporary staffing costs and 1,161 thousand euros in subcontracting costs, in line with the higher level of activity. This increase was partly offset by a decrease of 922 thousand euros in maintenance expenses. Professional fees remained relatively stable at -7,441 thousand euros (-7,258 thousand euros for the six months ended 30 June 2025, restated) and mainly related to strategic studies and support provided to the Group in connection with its external growth activities.

NOTE 8. Employee benefit expense

(in € thousands)	30 June 2026	30 June 2025 restated
Wages and salaries	-55,232	-45,403
Social security contributions	-14,588	-12,141
Post-employment benefits	358	-230
Other employee costs	-7,552	-9,855
EMPLOYEE BENEFIT EXPENSE	**-77,014**	**-67,629**

The increase in wages and salaries was due to the inclusion of employees from Noxant, NVLS and Phasics, which were acquired in 2025, and to growth-related increases in headcount.

Other employee benefit expenses mainly comprise statutory profit-sharing and incentive payments amounting to 6,203 thousand euros for the six months ended 30 June 2026 (5,510 thousand euros for the six months ended 30 June 2025 restated).

NOTE 9. Other operating income and expenses

The EXOSENS Group receives public financing in the form of grants for the development of certain projects. Investment grants are initially recognised at fair value when there is reasonable assurance that the grant will be received and that the Group will comply with all related conditions.

In accordance with IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, these advances are recognised in deferred income and released to profit or loss over the useful life of the related development costs.

Other operating income

(in € thousands)	30 June 2026	30 June 2025 restated
Investment grants	1,880	980
Other operating income	396	436
Other	51	168
TOTAL OTHER OPERATING INCOME	**2,328**	**1,584**

The increase in investment grants mainly reflects higher funding received for innovation projects, particularly the development of uncooled imaging technologies.

Other operating expenses

(in € thousands)	30 June 2026	30 June 2025 restated
Other operating expenses	-376	-361
Business acquisition costs	-1,449	-490
Other	-91	-1
TOTAL OTHER OPERATING EXPENSES	**-1,916**	**-853**

Other operating expenses totalling 376 thousand euros (2025: 361 thousand euros) correspond to various individually insignificant items.

NOTE 10. Depreciation, amortisation, impairment and provision charges, net of reversals

Depreciation, amortisation, impairment and provision charges (net of reversals) are broken down as follows:

(in € thousands)	Note	30 June 2026	30 June 2025 restated
On other non-current assets (excluding IFRS 16)	16/17	-17,551	-15,359
On brands	16	-28,160	
On other non-current assets (IFRS 16 restatement)	18	-2,157	-1,715
On impairment of current assets		1,219	-2,246
On provisions	26	405	815
On provisions not reflecting core operating performance		0	0
TOTAL CHARGES NET OF REVERSALS		**-46,244**	**-18,505**

The difference between the total above and the "Depreciation, amortisation, impairment and provision charges, net of reversals" line in the consolidated statement of cash flows corresponds to 101 thousand euros in reversals of provisions used during the period.

NOTE 11. Other income and expenses

Other income and expenses comprise items excluded from Management's performance assessment because of their nature or their material and unusual nature.

For the six months ended 30 June 2026, other income and expenses totalled 20 thousand euros (-41 thousand euros for the six months ended 30 June 2025 restated).

(in € thousands)	30 June 2026	30 June 2025 restated
Other	20	-41
OTHER INCOME AND EXPENSES	**20**	**-41**

NOTE 12. Net finance income/(expense)

The cost of net debt and other finance income and expenses break down as follows:

(in € thousands)	30 June 2026	30 June 2025 restated
Interest expense on bank borrowings	-5,676	-6,239
Interest expense on leases	-655	-404
Other finance expense	0	0
COST OF NET DEBT	**-6,330**	**-6,643**
Foreign exchange gains and losses	676	-2,253
Other financial gains/(losses) on derivative instruments	-193	-692
GAINS/(LOSSES) ON DERIVATIVE INSTRUMENTS	**483**	**-2,945**
Other*	-191	1,266
NET FINANCE INCOME/(EXPENSE)	**-6,038**	**-8,322**

- *The "Other" line includes the remeasurement of the put option over non-controlling interests, with an impact of -0.8 million euros.*

Interest expense on bank borrowings mainly relates to the 250 million euro term loan.

Foreign exchange gains/(losses) mainly arise from the effect of exchange-rate movements on intragroup current-account balances.

Finance income/(expense) from derivative instruments for the six months ended 30 June 2026 mainly relates to changes in the fair value of caps not designated for hedge accounting.

NOTE 13. Income tax

The tax expense amounted to 9,869 thousand euros for the six months ended 30 June 2026 compared with a tax expense of 11,087 thousand euros for the six months ended 30 June 2025 restated.

After taking into account the utilisation of tax loss carryforwards and dividend payments, the effective current tax rate is 26%.

The tax loss carryforward recognised as an asset by the French tax consolidation group was therefore reversed in an amount of 22.5 million euros at 30 June 2026.

Deferred tax income of 2.6 millions euros for the six months ended 30 June 2026 mainly arose from the reversal of deferred tax liabilities in connection with brand impairment (+7.6 million euros) and the utilisation of recognised tax loss carryforwards (-5.6 million euros).

(in € thousands)	30 June 2026	30 June 2025
Current tax expense	-12,436	-8,657
Deferred tax income/(expense) *(excluding brand impairment)*	-4,997	-2,430
Deferred tax income/(expense) relating to brand impairment	7,564	0
INCOME TAX	**-9,869**	**-11,087**

NOTE 14. Earnings per share

Basic earnings per share is calculated by dividing profit or loss attributable to the Company's shareholders by the weighted average number of shares outstanding during the period, excluding shares repurchased by the Group and held as treasury shares.

Diluted earnings per share are calculated by adjusting the weighted average number of shares outstanding to take into account the potentially dilutive effect of all equity instruments issued by the Company, including unvested performance shares. As at 30 June 2026, there are outstanding dilutive instruments related to the deferred matching contribution under the ExoShare plan and the performance share award plans. The impact on earnings per share is not material.

	30 June 2026	30 June 2025
PROFIT/(LOSS) (IN EUROS)	**15,339,685**	**27,909,421**
Profit/(loss) from continuing operations	**15,339,685**	29,611,974
Profit/(loss) from discontinued operations	0	-1,702,553
Weighted average number of shares	50,441,791	50,782,552
BASIC EARNINGS PER SHARE (IN EUROS)	**0.30**	**0.55**
Basic earnings per share from continuing operations (in euros)	0.30	0.58
Basic earnings per share from discontinued operations (in euros)	0.00	-0.03

NOTE 15. Goodwill

In accordance with IAS 36, Impairment of Assets, an entity must assess at each reporting date whether there is any indication that an asset may be impaired.

Recoverable amounts are determined on the basis of value-in-use calculations. In this context, the Group verified that the business plans prepared at the 2025 annual reporting date on the basis of management assumptions consistent with macroeconomic forecasts had not been materially called into question.

As at 30 June 2026, the Group did not identify any indications of impairment of the cash-generating units (CGUs) requiring the performance of specific impairment tests.

The methodologies applied by the Group as well as additional information are described in Note 15, "Goodwill", to the consolidated financial statements for the year ended 31 December 2025.

Goodwill changed as follows:

(in € thousands)	Gross value	Impairment losses	Total
AMOUNT AS AT 31 DECEMBER 2024	**189,495**	**0**	**189,495**
Translation adjustments	-957	0	-957
Changes in consolidation scope	47,564	0	47,564
Impairment, net	0	0	0
Other	-2,770	0	-2,770
AMOUNT AS AT 31 DECEMBER 2025	**233,332**	**0**	**233,332**
Translation adjustments	109	0	109
Changes in consolidation scope	0	0	0
Impairment, net	0	0	0
Other	0	0	0
AMOUNT AS AT 30 JUNE 2026	**233,441**	**0**	**233,441**

As at 30 June 2026, goodwill was allocated to CGUs as follows:

(in € thousands)	30 June 2026	31 December 2025
Amplification	99,353	99,353
Detection & Imaging	134,087	133,978
GOODWILL	**233,441**	**233,332**

NOTE 16. Intangible assets

The following table provides details regarding the Group's intangible assets:

(in € thousands)	Development costs and technologies	Software, concessions, patents	Customer relationships and brands	Other intangible assets	TOTAL
GROSS AMOUNT AS AT 31 DECEMBER 2024	**93,400**	**5,250**	**152,016**	**11,084**	**261,751**
Changes in consolidation scope	16,729	221	22,222	-52	39,120
Acquisitions	13,714	422	0	3,783	17,918
Disposals	0	-55	0	-32	-87
Translation adjustments	-1,140	-393	-1,063	-256	-2,852
Transfers and other	-7,945	0	-10,015	-461	-18,422
GROSS AMOUNT AS AT 31 DECEMBER 2025	**114,758**	**5,446**	**163,159**	**14,066**	**297,428**
Changes in consolidation scope	0	0	0	0	0
Acquisitions	9,170	439	0	1,133	10,742
Disposals	-578	0	0	-27	-605
Translation adjustments	512	159	823	-8	1,486
Transfers and other	-13,082	28	0	0	-13,053
GROSS AMOUNT AS AT 30 JUNE 2026	**110,780**	**6,072**	**163,983**	**15,163**	**295,998**

(in € thousands)	Development costs and technologies	Software, concessions, patents	Customer relationships and brands	Other intangible assets	TOTAL
AMORTISATION AND IMPAIRMENT AS AT 31 DECEMBER 2024	**-28,476**	**-2,463**	**-25,362**	**-522**	**-56,822**
Changes in consolidation scope	0	0	0	0	0
Amortisation	-12,634	-824	-11,082	-324	-24,864
Impairment, net	0	0	0	-589	-589
Disposals	0	19	0	0	19
Translation adjustments	159	485	89	44	777
Transfers and other	5,863	-7	4,021	-29	9,848
AMORTISATION AND IMPAIRMENT AS AT 31 DECEMBER 2025	**-35,087**	**-2,789**	**-32,334**	**-1,420**	**-71,630**
Changes in consolidation scope	0	0	0	0	0
Amortisation	-4,874	-372	-5,467	-141	-10,854
Impairment, net	0	0	-28,160	-590	-28,750
Disposals	20	0	0	0	20
Translation adjustments	-140	-128	-262	2	-529
Transfers and other	13,048	0	0	34	13,082
AMORTISATION AND IMPAIRMENT AS AT 30 JUNE 2026	**-27,033**	**-3,289**	**-66,223**	**-2,116**	**-98,661**

NET AMOUNTS AS AT 30 JUNE 2026	**83,747**	**2,783**	**97,759**	**13,047**	**197,337**
NET AMOUNTS AS AT 31 DECEMBER 2025	**79,670**	**2,657**	**130,825**	**12,646**	**225,798**
NET AMOUNTS AS AT 31 DECEMBER 2024	**64,925**	**2,787**	**126,654**	**10,562**	**204,928**

Development costs and technologies

As at 30 June 2026, the net carrying amount of development costs and technologies recognised in the consolidated statement of financial position was 83,747 thousand euros (31 December 2025: 79,670 thousand euros), of which 26,277 thousand euros related to technologies. This net carrying amount relates to projects for the development of new products and services. Research and development costs that were not capitalised, net of grants and other tax credits relating to research and development, amounted to 6,161 thousand euros for the six months ended 30 June 2026 (for the year ended 31 December 2025: 13,975 thousand euros).

Brands

As at 30 June 2026, the net carrying amount of the brands recognised in the consolidated statement of financial position was nil (31 December 2025: 28,431 thousand euros) following the impairment of the Photonis, Telops and Xenics brands. This impairment arose from the unification of all the Group's brands under the single EXOSENS brand identity during the first half of 2026.

Customer relationships

As at 30 June 2026, customer relationships are recognised in the consolidated statement of financial position at a carrying amount of 97,759 thousand euros (31 December 2025: 102,394 thousand euros).

This amount mainly corresponds to the value of customer lists recognised in business combinations, particularly those involving EXOSENS International, Xenics, Telops, El-Mul, Centronic, Noxant and Phasics, and to the value attributed to the order backlog as part of the allocation of NVLS goodwill.

NOTE 17. Property, plant and equipment

The Group's main categories of property, plant and equipment as at 30 June 2026 are as follows:

(in € thousands)	Land	Buildings	Technical installations	Other	PP&E under construction	TOTAL
GROSS AMOUNT AS AT 31 DECEMBER 2024	**2,798**	**22,111**	**58,490**	**6,241**	**27,975**	**117,615**
Changes in consolidation scope	0	5	1,629	695	0	2,329
Acquisitions	53	3,239	10,655	1,077	18,570	33,594
Disposals	0	0	-303	36	22	-245
Translation adjustments	0	-328	-2,203	-391	-425	-3,347
Transfers and other	340	881	-2,058	-628	-11,304	-12,771
GROSS AMOUNT AS AT 31 DECEMBER 2025	**3,190**	**25,907**	**66,210**	**7,029**	**34,838**	**137,175**
Changes in consolidation scope	0	0	0	0	0	0
Acquisitions	0	6	2,010	924	18,453	21,393
Disposals	0	0	-530	-5	0	-535
Translation adjustments	0	181	779	176	45	1,181
Transfers and other	280	3,435	4,631	284	-9,026	-396
GROSS AMOUNT AS AT 30 JUNE 2026	**3,470**	**29,530**	**73,100**	**8,408**	**44,309**	**158,817**

(in € thousands)	Land	Buildings	Technical installations	Other	PP&E under construction	TOTAL
DEPRECIATION AND IMPAIRMENT AS AT 31 DECEMBER 2024		**-4,147**	**-17,313**	**-2,594**	**0**	**-24,054**
Change in consolidation scope		0	0	0	0	0
Depreciation		-1,978	-7,270	-1,250	0	-10,497
Impairment, net		0	0	0	0	0
Disposals		0	220	11	0	230
Translation adjustments		92	1,665	350	0	2,107
Transfers and other		584	6,158	1,370	0	8,112
DEPRECIATION AND IMPAIRMENT AS AT 31 DECEMBER 2025		**-5,448**	**-16,540**	**-2,113**	**0**	**-24,101**
Change in consolidation scope		0	0	0	0	0
Depreciation		-1,223	-4,273	-769	0	-6,265
Impairment, net		0	0	0	0	0
Disposals		0	450	4	0	455
Translation adjustments		-57	-473	-147	0	-676
Transfers and other		0	371	0	0	371
DEPRECIATION AND IMPAIRMENT AS AT 30 JUNE 2026		**-6,728**	**-20,464**	**-3,025**	**0**	**-30,217**

NET AMOUNTS AS AT 30 JUNE 2026	**3,470**	**22,802**	**52,636**	**5,383**	**44,309**	**128,600**
NET AMOUNTS AS AT 31 DECEMBER 2025	**3,190**	**20,459**	**49,670**	**4,916**	**34,838**	**113,073**
NET AMOUNTS AS AT 31 DECEMBER 2024	**2,798**	**17,964**	**41,177**	**3,647**	**27,975**	**93,561**

NOTE 18. Right-of-use assets

Right-of-use assets changed as follows:

	IFRS 16 right-of-use assets			
(in € thousands)	Buildings	Technical equipment	Other	Total
GROSS AMOUNTS AS AT 1 JANUARY 2025	**13,208**	**4,633**	**50**	**17,891**
Changes in consolidation scope	2,978	784	-52	3,710
Acquisitions	8,878	721	0	9,599
Disposals	-515	-858	0	-1,373
Translation adjustments	-817	-17	-2	-836
Transfers and other	-6,837	-357	0	-7,194
GROSS AMOUNT AS AT 31 DECEMBER 2025	**16,894**	**4,907**	**-4**	**21,796**
DEPRECIATION AND IMPAIRMENT AS AT 1 JANUARY 2025	**-5,025**	**-2,273**	**-34**	**-7,332**
Change in consolidation scope	0	-274	34	-240
Depreciation	-2,938	-1,411	0	-4,349
Disposals	408	872	0	1,280
Translation adjustments	537	17	1	556
Transfers and other	3,084	238	0	3,321
DEPRECIATION AND IMPAIRMENT AS AT 31 DECEMBER 2025	**-3,935**	**-2,831**	**1**	**-6,764**
GROSS AMOUNTS AS AT 1 JANUARY 2026	**16,894**	**4,907**	**-4**	**21,796**
Changes in consolidation scope	0	0	0	0
Acquisitions	1,893	591	0	2,483
Disposals	-194	-396	0	-589
Translation adjustments	486	23	0	509
Transfers and other	0	0	0	0
GROSS AMOUNT AS AT 30 JUNE 2026	**19,079**	**5,125**	**-4**	**24,200**
DEPRECIATION AND IMPAIRMENT AS AT 1 JANUARY 2026	**-3,935**	**-2,831**	**1**	**-6,764**
Change in consolidation scope	0	0	0	0
Depreciation	-1,397	-601	0	-1,998
Disposals	194	396	0	589
Translation adjustments	-274	-11	0	-285
Transfers and other	0	-3	2	-1
DEPRECIATION AND IMPAIRMENT AS AT 30 JUNE 2026	**-5,413**	**-3,050**	**4**	**-8,459**
NET RIGHT-OF-USE ASSETS AS AT 30 JUNE 2026	**13,666**	**2,075**	**-1**	**15,741**
NET RIGHT-OF-USE ASSETS AS AT 31 DECEMBER 2025	**12,959**	**2,076**	**-3**	**15,032**

The increase in IFRS 16 right-of-use assets was mainly attributable to new property leases in the United States and new leases for production equipment in France and the Netherlands.

NOTE 19. Investments in equity-accounted companies and other investments

(in € thousands)	Total
AS AT 1 JANUARY 2025	**3,414**
Change in consolidation scope	200
Acquisitions of equity investments	294
Share of profit/(loss) of equity-accounted investees	0
Translation adjustments	-39
Impairment	0
AS AT 31 DECEMBER 2025	**3,840**
AS AT 1 JANUARY 2026	**3,840**
Change in consolidation scope	0
Acquisitions of equity investments	4,499
Share of profit/(loss) of equity-accounted investees	0
Translation adjustments	62
Impairment	0
AS AT 30 JUNE 2026	**8,459**

As at 30 June 2026, changes in investments were as follows:

- the acquisition of 100% of the shares of the Finnish company Emberion for 2,506 thousand euros. This investment was not included in the consolidation scope as at 30 June 2026 and will be included starting from the second half of 2026 (Note 3);
- the acquisition of an additional equity interest in Adelphi Technology Inc. for 1,993 thousand euros, bringing the Group's stake to 29.99%. Given the Group's significant influence over this entity, the investment is accounted for using the equity method in accordance with IAS 28 (Note 3).

No indications of impairment were identified as at 30 June 2026.

NOTE 20. Inventories

Inventories break down as follows:

(in € thousands)	30 June 2026	31 December 2025
Raw materials	58,807	50,888
Work in progress	55,601	50,621
Finished goods	26,059	21,576
Bought-in goods	350	243
INVENTORIES – GROSS VALUE	**140,817**	**123,328**
Provision for obsolescence	-17,560	-18,240
INVENTORIES – NET VALUE	**123,257**	**105,088**

As at 30 June 2026, the increase in inventories amounted to 17,489 thousand euros, in connection with the activity and in order to prepare for deliveries in the second half of 2026.

NOTE 21. Trade receivables

The carrying amount of trade receivables breaks down as follows:

(in € thousands)	30 June 2026	31 December 2025
Trade receivables – gross value	68,695	66,205
Unbilled receivables	8,341	8,236
Loss allowance on trade receivables	-1,024	-1,316
TRADE RECEIVABLES – NET	**76,011**	**73,125**

As at 30 June 2026, the increase in trade receivables was mainly attributable to strong revenue growth in the first six months, partially offset by improved customer payment times.

The loss allowance on trade receivables amounted to 1,024 thousand euros as at 30 June 2026 (31 December 2025: 1,316 thousand euros).

NOTE 22. Current financial assets and other current assets

Current financial assets and other current assets break down as follows:

(in € thousands)	30 June 2026	31 December 2025
VAT and other tax receivables	12,333	13,269
Income tax	10,868	11,354
Other receivables*	13,073	8,435
Tax and employee-related receivables	121	182
Current financial assets	426	11
CURRENT FINANCIAL ASSETS AND OTHER CURRENT ASSETS	**36,821**	**33,252**

* *Including 6.0 million euros in prepaid expenses (6.9 million euros as at 30 June 2025), 2.5 million euros in current-account advances related to the acquisition of Emberion, 1.7 million euros in advances related to the disposal of the MA business in 2025 and 1.6 million euros in other receivables (1.9 million euros as at 30 June 2025).*

NOTE 23. Cash and cash equivalents

Cash and cash equivalents break down as follows:

(in € thousands)	30 June 2026	31 December 2025
Cash and cash equivalents	68,794	58,110
Bank deposits subject to a notice period up to three months	14	10,406
Accrued interest receivable	0	102
Cash and cash equivalents	**68,808**	**68,618**
Bank overdrafts	1	0
CASH AND CASH EQUIVALENTS NET OF BANK OVERDRAFTS	**68,807**	**68,617**

Accrued interest receivable as at 30 June 2026 does not qualify as cash and is presented under current financial assets (Note 22).

NOTE 24. Share capital and share premiums

Issued capital

As at 30 June 2026, the Company's issued share capital amounted to 21,648,119 euros and consists of 50,936,749 ordinary shares with a nominal value of 0.425 euros each, fully subscribed and paid up.

These issues included total share premiums of 346,763 thousand euros.

HLD Europe is the majority shareholder.

Rights, preferences and restrictions of each share class

The following table presents outstanding ordinary and preference shares:

(in thousands of shares)	Ordinary shares	Preference shares	Total
AS AT 1 JANUARY 2025	**50,783**		**50,783**
Capital subscription			0
Increase	154		154
Decrease			0
AS AT 31 DECEMBER 2025	**50,937**	**0**	**50,937**

(in thousands of shares)	Ordinary shares	Preference shares	Total
AS AT 1 JANUARY 2026	**50,937**		**50,937**
Capital subscription	0		0
Increase	0		0
Decrease	0		0
AS AT 30 JUNE 2026	**50,937**	**0**	**50,937**

As at 30 June 2026, the Company held 25,873 treasury shares under the liquidity agreement with Kepler Cheuvreux. This agreement was put in place on 8 July 2024 to enhance the liquidity of the Company's shares on Euronext Paris, for an amount up to 2 million euros. It runs for an initial period to 30 June 2026 and is renewable by tacit agreement for successive periods of one year. These are the only treasury shares held by the Company.

A 2025–2026 LTIP was implemented following a decision by the Board of Directors on 28 February 2025. It concerns 234,500 shares (approximately 0.46% of the Company's share capital) allocated to the managers and employees of the Company and its subsidiaries. These share awards are subject to a two-year vesting period and a one-year holding period and are conditional on the achievement of collective financial and CSR targets.

A 2026–2028 LTIP was implemented following a decision by the Board of Directors on 20 February 2026. It concerns 197,000 shares (approximately 0.39% of the Company's share capital) allocated to the managers and employees of the Company and its subsidiaries. These share awards are subject to a three-year vesting period and a one-year holding period and are conditional on the achievement of collective financial and CSR targets.

The share capital is 21,648,119 euros divided into 50,936,749 shares with a nominal value of 0.425 euros.

NOTE 25. Financial liabilities

The carrying amount of financial liabilities is detailed below:

(in € thousands)	Note	30 June 2026 Total	30 June 2026 Current	30 June 2026 Non-current	31 December 2025 Total	31 December 2025 Current	31 December 2025 Non-current
Term Loan B[(1)]		247,134	0	247,134	246,869	0	246,869
Lease liabilities[(2)]		17,750	4,970	12,781	16,616	2,971	13,645
Other financial liabilities[(3)]		4,551	245	4,306	2,868	457	2,412
Accrued interest[(4)]		36	36	0	36	36	0
Bank overdrafts		1	1	0	0	0	0
FINANCIAL LIABILITIES		**269,472**	**5,251**	**264,221**	**266,389**	**3,463**	**262,926**
Derivative financial instruments (liabilities)	30	0	0	0	76	76	0
Derivative financial instruments (assets)	30	-848	-848	0	-146	-146	0
DERIVATIVE FINANCIAL INSTRUMENTS (NET)		**-848**	**-848**	**0**	**-71**	**-71**	**0**
Cash and cash equivalents	23	-68,794	-68,794	0	-58,110	-58,110	0
Bank deposits subject to a notice period of up to three months	23	-14	-14	0	-10,406	-10,406	0
Accrued interest receivable					-102	-102	
CASH AND CASH EQUIVALENTS		**-68,808**	**-68,808**	**0**	**-68,618**	**-68,618**	**0**
Accrued interest receivable		-385	-385				
TOTAL NET FINANCIAL LIABILITIES		**199,816**	**-64,405**	**264,221**	**197,701**	**-65,225**	**262,926**

(1) The amount of the term loan (Term Loan B) includes a gross amount equal to 250.0 million euros, less 3.9 million euros in borrowing costs. The presentation of the liabilities takes account of the effective interest rate (EIR), in accordance with IFRS 9.

(2) The increase in lease liabilities was due to extensions of property leases.

(3) Other financial debts mainly correspond to several loans taken out by Photonis France (3.6 million euros), Phasics (0.6 million euros) and Xenics (0.2 million).

(4) Interest accrued in 2026 mainly relates to the term loan. Interest accrues and is payable in accordance with the contractual terms of the debt.

The pledges and commitments given by the Group in respect of financial liabilities are presented in Note 29, "Off-balance sheet commitments".

Changes in financial liabilities and derivative instruments are broken down by type of movement in the table below:

(in € thousands)	Opening as at 1 January 2025	Cash flow: Inflows	Cash flow: Outflows	Non-cash movements: Accrued interest	Non-cash movements: Changes in consolidation scope	Non-cash movements: Other variations	Total non-cash	31/12/2025
Bonds, borrowings and other	247,785	1,460	0	0	1,170	-1,135	35	249,281
Lease liabilities	8,175	0	0	0	3,426	2,044	5,470	13,645
NON-CURRENT FINANCIAL LIABILITIES	**255,961**	**1,460**	**0**	**0**	**4,596**	**909**	**5,505**	**262,926**
Bonds, borrowings and other	2,660	33	-3,972	-229	1,442	558	1,772	493
Lease liabilities	2,724	0	-3,432	0	159	3,519	3,678	2,971
Overdrafts	314	0	-300	0	2	-17	-14	0
CURRENT FINANCIAL LIABILITIES	**5,698**	**33**	**-7,703**	**-229**	**1,604**	**4,061**	**5,436**	**3,463**
TOTAL FINANCIAL LIABILITIES	**261,659**	**1,493**	**-7,703**	**-229**	**6,199**	**4,970**	**10,941**	**266,389**
Derivative instrument assets	-6	0	0	0	0	-141	-141	-147
Derivative instrument liabilities	136	0	0	0	0	-61	-61	76
Net impact (inflows/outflows) in the consolidated statement of cash flows		-6,211						

		Cash flow		Non-cash movements				
(in € thousands)	Opening as at 1 January 2026	Inflows	Outflows	Accrued interest	Changes in consolidation scope	Other variations	Total "non-cash"(1)	30/6/2026
Bonds, borrowings and other	249,281	2,227	0	0	0	-67	-67	251,440
Lease liabilities	13,645	0	0	0	0	-864	-864	12,781
NON-CURRENT FINANCIAL LIABILITIES	**262,926**	**2,227**	**0**	**0**	**0**	**-931**	**-931**	**264,221**
Bonds, borrowings and other	493	0	-473	0	0	261	261	281
Lease liabilities	2,971	0	-1,616	0	0	3,615	3,615	4,970
Overdrafts	0	1	0	0	0	0	0	1
CURRENT FINANCIAL LIABILITIES	**3,463**	**1**	**-2,089**	**0**	**0**	**3,876**	**3,876**	**5,251**
TOTAL FINANCIAL LIABILITIES	**266,389**	**2,227**	**-2,089**	**0**	**0**	**2,945**	**2,945**	**269,472**
Derivative instrument assets	-147	0	0	0	0	-702	-702	-849
Derivative instrument liabilities	76	0	0	0	0	-76	-76	0
Net impact (inflows/outflows) in the consolidated statement of cash flows(2)		138						

(1) Other non-cash movements mainly comprise the amortisation of debt issuance costs and the increase in lease liabilities arising from new leases.

(2) The total of the lines in the consolidated statement of cash flows cross-referenced to Note 25 shows a difference of 0.4 million euros corresponding to the term loan renegotiation costs.

Financing structure

As part of its successful IPO on 7 June 2024, EXOSENS established a Senior Credit Agreement including two lines of credit with a maximum total amount of 350 million euros, including:

- a 5-year term loan of a maximum amount of 250 million euros, paying interest ranging from 1.50% to 2.50% + 3-month Euribor, repayable on maturity; and
- a 5-year revolving credit facility (RCF) with a maximum amount of 100 million euros, paying interest ranging from 1.50% to 2.50% + 3-month Euribor.

On 3 June 2026, the Group renegotiated certain terms of its bank financing. As part of the renegotiation, the margin applicable to the term loan was revised and now ranges from 0.95% to 1.75% in addition to three-month Euribor. The revolving credit facility, which was undrawn as at 30 June 2026, bears interest at three-month Euribor plus a margin ranging from 0.55% to 1.75%. In addition, the Group exercised the accordion feature under the financing agreement, increasing the capacity of the revolving credit facility from 100 million euros to 200 million euros and thereby strengthening its financial flexibility and its ability to finance its development projects.

On 24 June 2026, EXOSENS entered into a credit facility of up to 140 million euros with the European Investment Bank, with a maturity of up to seven years and repayable at maturity.

Financial covenants

The syndicated loan agreement contains a financial covenant requiring compliance with a leverage ratio calculated as the ratio of consolidated net debt to consolidated adjusted EBITDA.

As at 30 June 2026, the leverage ratio had to be below 3.00 for the term loan agreement (Term Loan B).

The Group's leverage ratio as at 30 June 2026 was 1.2x (unaudited data).

The Group regularly monitors compliance with its financial covenants. The Group did not breach its leverage ratio covenants in financial years 2025 and 2026.

There are no financial covenants based on Group consolidated equity.

NOTE 26. Provisions and other liabilities

Provisions and other liabilities amounted to 101,043 thousand euros as at 30 June 2026 (as at 31 December 2025: 93,141 thousand euros) and mainly comprise provisions for customer warranties, payroll tax liabilities and amounts payable to the State.

Provisions

In the ordinary course of the Group's business activities, the Company and its subsidiaries have entered into various warranty contracts that include compensation and guarantee provisions, especially in the case of product returns. The Group records a provision for these guarantees, based on statistical product return rates. The Group recognises provisions for litigation when it is probable that present obligations arising from past events will give rise to an outflow of resources with no equivalent consideration and a reliable estimate can be made of the obligation. Provisions are also recognised when the Group identifies probable or certain obligations related to future commitments whose amount or timing is uncertain.

(in € thousands)	Provisions for litigation	Customer warranties	Other provisions	Total
OPENING AS AT 1 JANUARY 2025	**1,410**	**2,264**	**5,195**	**8,869**
Changes in consolidation scope	0	0	3	3
Additions	208	931	1,808	2,947
Reversals	-1,410	-583	-4,452	-6,444
Reclassification	0	1	0	1
Other movements	0	0	0	0
Translation adjustments	0	-63	-9	-72
AS AT 31 DECEMBER 2025	**208**	**2,550**	**2,546**	**5,304**
OPENING AS AT 1 JANUARY 2026	**208**	**2,550**	**2,546**	**5,304**
Changes in consolidation scope	0	0	0	0
Additions	0	195	143	338
Reversals	0	-356	-506	-862
Reclassification	0	0	0	0
Other movements	0	0	0	0
Translation adjustments	0	9	0	9
AS AT 30 JUNE 2026	**208**	**2,398**	**2,183**	**4,789**

Other non-current and current liabilities

Other non-current liabilities totalled 8,377 thousand euros (as at 31 December 2025: 10,034 thousand euros) and mainly relate to research and development grants amounting to 6,617 thousand euros.

Other current liabilities break down as follows:

(in € thousands)	30 June 2026	31 December 2025
Social security liabilities	30,669	31,209
VAT and other taxes	20,058	11,901
Accrued expenses	9,948	8,885
Capital expenditure payables	2,472	2,846
Advances and down payments received on orders	16,072	13,495
Miscellaneous liabilities*	8,658	9,467
OTHER CURRENT LIABILITIES	87,877	77,802

* *Miscellaneous liabilities mainly comprise contingent consideration liabilities of 3.8 million euros, a deposit of 1.7 million euros received in connection with litigation and 1.1 million euros relating to research tax credits.*

As at 30 June 2026, the increase in other current liabilities was mainly attributable to higher advances and down payments received on orders and increases in amounts payable to the State and social security bodies.

NOTE 27. Post-employment benefit obligations

The Group has commitments under long-term employee benefit plans. In accordance with IAS 19, Employee Benefits, the obligation to provide benefits under defined benefit plans is determined by independent actuaries using the projected unit credit actuarial valuation method.

As at 30 June 2026, provisions for post-employment benefit obligations amounted to 7,750 thousand euros (7,864 thousand euros as at 31 December 2025).

They include provisions for post-employment benefits and provisions for supplementary pension commitments and mainly concern France.

The net benefit expense recognised in the first half of 2026 for pension commitments is equal to 50% of the projected expense for the 2026 financial year determined on the basis of actuarial assumptions as at 31 December 2025 in accordance with the provisions of IAS 19 and in the absence of significant market fluctuations occurring since the end of the previous financial year.

The details of the benefits received by the Group's employees are presented in Note 29 "Commitments for post-employment benefits" to the consolidated financial statements for the financial year ended 31 December 2025.

NOTE 28. Trade payables

(in € thousands)	30 June 2026	31 December 2025
Amounts due to suppliers	22,990	19,536
Purchase invoice accruals	11,141	11,632
Notes payable	1,503	28
TRADE PAYABLES	**35,633**	**31,196**

NOTE 29. Off-balance sheet commitments

As at 30 June 2026	Type of commitments	Commitments given
Exosens SA	Guarantee	Bank guarantee of €127,191 (BNP) relating to the lease for EXOSENS' premises at 18 avenue de Pythagore, Mérignac (signed on 22 July 2022, with the lease term running from 1 July 2022 to 30 June 2031). Guarantee issued on 31 December 2022 by BNP in favour of *Société Épargne Foncière*. Following the sale of the property by *Épargne Foncière* to *Société BAGAN AMBRE* on 25 July 2024, the new owner confirmed that the guarantor remained liable to it and that the guarantee remained in effect, without the need to issue a new guarantee in the name of BAGAN Ambre and obtain the release of the previous guarantee.
	Joint and several guarantee	If a subsidiary were to draw on EXOSENS' financing facilities (the term loan or the RCF), EXOSENS would automatically become jointly and severally liable as guarantor
	Joint and several guarantee	Joint and several guarantee of 40 million euros provided to Citi in connection with the establishment of cash pooling
	RCF (Revolving Credit Facility)	Financing line of 200 million euros granted by a pool of banks – end of commitment June 2029
	Loan	A 140 million euro financing facility from the European Investment Bank, with a maximum term of seven years, repayable at maturity and available for drawdown for 36 months, including a 12-month grace period.
Exosens International SAS	Guarantees	A corporate guarantee of 800 thousand euros was granted to the Spanish Ministry of Defence to secure the commitments made by Exosens International in connection with the foreign investment review relating to NVLS. The guarantee is in force for eight years from 8 July 2025, unless released early if (a) Exosens International ceases to control NVLS or (b) NVLS ceases to carry on its defence-related activities.
PHOTONIS France SAS	Guarantees given in respect of foreign export contracts	AED 4.7 M performance bond (CIC)
		INR 0.5 million earnest money deposit (EMD) guarantee (CIC)
		EUR 1.0 million performance bond (CIC + BNP)
		EUR 0.5 M guarantee (CIC + LCL)
		INR 2.0 M performance bond (CIC)
		EUR 1.5 M advance payment guarantee (BNP)
		EUR 0.02 million customs bond (SG)
	Loan	Loan agreement for EUR 7.85 million – EUR 3.6 million drawn as at 30 June 2026
	Loan	Loan agreement for EUR 1.25 million – undrawn as at 30 June 2026
PHOTONIS Germany	Customs guarantee	EUR 0.01 million bond in favour of the Darmstadt Custom Office (Zollamt Darmstadt) issued by Volksbank Kurpfalz.
Exosens Detection Israel Ltd	Guarantee issued for a lease	ILS 1.4 million bank guarantee with counter-guarantee issued by BNP
	Deposit	ILS 0.4 million deposit at the bank for account operation and bank cards
Telops	Guarantee given to banks	CAD 2 M guarantee given for the bank margin (EDC)
	Guarantees given to banks	CAD 1.5 M guarantee given for ATA carnets
	Other commitments	Commitments to purchase goods from various suppliers totalling USD 5.4 M, CAD 0.8 M and EUR 0.1 M
NVLS	Guarantee issued for the Kuwait MOD	Bank guarantee for EUR 0.2 million
	Guarantee issued for a lease	Bank guarantee for EUR 0.04 million
	Guarantee issued for the Spanish MOD	Bank guarantee for EUR 3.0 million

NOTE 30. Financial risk management

Risks

The Group's activities expose it to a variety of financial risks: market risk (including interest rate risk and foreign exchange risk), credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance. The Group uses derivative financial instruments to hedge certain risk exposures.

Risk management arrangements

The Group uses derivative financial instruments to manage foreign exchange risk and interest rate risk on borrowings.

Most of the financial instruments entered into by the Group are interest rate caps and swaps and forward purchases and sales of foreign currencies. These derivatives were entered into to protect the Group against both increases in interest rates and adverse movements in exchange rates. By offsetting market risks on the underlying liabilities with derivatives, the Group manages the concentration of risk on its financial liabilities.

In addition, to protect against counterparty risk on derivatives, the Group enters into contracts with several banks.

For all financial instruments, the carrying amount best represents the maximum exposure to credit risk.

The financial risk management policy and procedures defined by the Group are identical to those described in Note 32, "Financial risk management", to the consolidated financial statements for the year ended 31 December 2025.

Hedging transactions entered into or unwound during the period did not significantly change the EXOSENS Group's exposure to financial risks. The main risks (liquidity risk, foreign exchange risk, interest rate risk, credit and counterparty risk) are described in this note to the consolidated financial statements for the year ended 31 December 2025.

Derivative financial instruments

Financial instruments break down as follows:

	30 June 2026		31 December 2025	
(in € thousands)	Assets	Liabilities	Assets	Liabilities
CURRENT PORTION	**0**	**0**	**0**	**0**
Caps/Floors	848	0	146	0
TOTAL	**848**	**0**	**146**	**0**
NON-CURRENT PORTION	**0**	**0**	**0**	**0**
Caps/Floors	0	0	0	76
TOTAL	**0**	**0**	**0**	**76**

The carrying amount best represents the maximum exposure to credit risk for all derivatives subscribed to by the Group (no collateral held as a guarantee, etc.).

The total fair value of a hedging derivative is classified as a non-current asset or liability if the remaining maturity of the hedged item is more than 12 months and as a current asset or liability if the maturity of the hedged item is less than 12 months.

As at 30 June 2026, the derivative financial instruments used by the Group break down as follows:

Company	Instrument	Nominal amount	Maturity	Bank
EXOSENS	Swaps	€25 million	31/12/2026	BNP PARIBAS
EXOSENS	Swaps	€25 million	31/12/2026	CIC
EXOSENS	Swaps	€25 million	31/12/2026	ARKEA
EXOSENS	Swaps	€50 million	31/12/2026	BNP PARIBAS
EXOSENS	Swaps	€50 million	31/12/2027	BANQUE POSTALE
EXOSENS	Swaps	€25 million	31/12/2027	CIC
EXOSENS	Swaps	€50 million	31/12/2028	BNP PARIBAS
EXOSENS	Swaps	€25 million	31/12/2028	LCL
EXOSENS	Swaps	€25 million	31/12/2028	CIC
EXOSENS	Swaps	€25 million	31/12/2028	ARKEA
EXOSENS	CAP	€50 million	31/12/2026	BANQUE POSTALE
EXOSENS	CAP	€75 million	31/12/2027	BANQUE POSTALE
EXOSENS	CAP	€25 million	31/12/2027	BANQUE POSTALE

Financial instruments and fair-value estimation

Accounting policy

IFRS 13 requires the valuation techniques used for each financial asset and liability to be classified within a fair-value hierarchy.

The categories are defined as follows:

- level 1: direct reference to quoted prices (unadjusted) in active markets, for identical assets or liabilities;
- level 2: valuation techniques based on inputs other than quoted prices that are observable, either directly or indirectly;
- level 3: valuation techniques based on non-observable inputs.

The fair value of financial assets and liabilities recognised at amortised cost is close to the carrying amount, except for financial debt.

The fair value of financial liabilities is determined for each borrowing by discounting future cash flows at a rate based on the Euribor yield curve at the reporting date, adjusted for the Group's credit risk (Level 2).

The fair value of derivatives is measured using models commonly used to value these financial instruments (models integrating observable market inputs). The inclusion of counterparty default risk and the specific credit risk of the entity does not have a material impact on the fair value of derivatives.

Financial instruments break down as follows:

			Financial instruments by category				Fair Value Assumptions			
(in € thousands)	Net carrying amount	Cash and cash equivalents	Loans and receivables	Other financial liabilities at amortised cost	Assets/ liabilities at fair value through profit or loss	Hedging financial derivatives	Fair value	Level 1(1)	Level 2(2)	Level 3(3)
Non-current financial assets	653		653				653	653		
Derivative financial instruments	848				37	812	848		848	
Trade receivables	68,695		68,695				68,695	68,695		
Other current assets	26		26				26	26		
Current financial assets	426		426				426	426		
Cash and cash equivalents	68,808	68,808					68,808	68,808		
TOTAL ASSETS	**139,456**	**68,808**	**69,799**	**0**	**37**	**812**	**139,456**	**138,607**	**848**	**0**
Loans and borrowings	269,472			269,472			269,472	269,472		
Derivative financial instruments	0					0	0		0	
Trade payables	22,990			22,990			22,990	22,990		
Other current liabilities(4)	22,257			22,257			22,257	22,257		
TOTAL LIABILITIES	**314,719**	**0**	**0**	**314,719**	**0**	**0**	**314,719**	**314,719**	**0**	**0**

(1) Quoted prices (unadjusted) in active markets for identical assets or liabilities.

(2) Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).

(3) Data relating to the asset or liability that are not based on observable market data (unobservable data).

(4) "Other current liabilities" mainly comprise accrued supplier invoices of 11.1 million euros, other liabilities of 4.8 million euros, contingent consideration liabilities of 3.8 million euros and amounts payable to suppliers of property, plant and equipment of 2.5 million euros.

The fair value of debt is not materially different from its carrying amount as the debt was recently taken out.

Loans and borrowings include variable-rate loans from banks and fixed-rate shareholder loans which cannot be traded.

There is no material customer concentration risk.

Capital management

The Group's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain the future development of the business.

NOTE 31. Consolidated companies

The Group's legal entities ("the Entities") have been consolidated using the full consolidation or equity method and using the functional currencies listed below:

Fully consolidated entities as at 30 June 2026	% interest	% control	Functional currency
Exosens		Parent company	EUR
Exosens International	100.0%	100.0%	EUR
Photonis France	100.0%	100.0%	EUR
Photonis Netherlands B.V.	100.0%	100.0%	EUR
Imagine Sensors International	100.0%	100.0%	EUR
Photonis Infrared France	100.0%	100.0%	EUR
Exosens Holding USA Inc.	100.0%	100.0%	USD
Exosens Scientific USA Inc.	100.0%	100.0%	USD
Photonis Defense Inc.	100.0%	100.0%	USD
Photonis Shenzhen Technologies	100.0%	100.0%	CNY
Xenics NV	100.0%	100.0%	EUR
Xenics Inc.	100.0%	100.0%	USD
Sinfrared	100.0%	100.0%	EUR
Telops France	100.0%	100.0%	EUR
Telops Inc.	100.0%	100.0%	CAD
Telops USA Inc.	100.0%	100.0%	USD
Exosens Detection Israel Ltd.	100.0%	100.0%	ILS
Photonis Germany	100.0%	100.0%	EUR
Exosens UK	100.0%	100.0%	GBP
Centronic Limited	100.0%	100.0%	GBP
Centronic Holdings Limited	100.0%	100.0%	GBP
Centronic Group Limited	100.0%	100.0%	GBP
Exosens Spain	100.0%	100.0%	EUR
NVLS S.L	100.0%	85.0%	EUR
Noxant France S.A.S	100.0%	100.0%	EUR
Photonis USA Night Vision	100.0%	100.0%	USD
Phasics	100.0%	100.0%	EUR
Phasics Corp	100.0%	100.0%	USD

Equity-accounted entities	% interest	% control	Functional currency
IGG Photonis Night Vision Electronics and Equipment Repairs and Testing LLC	49.0%	49.0%	AED
Adelphi Technology Inc.	30.0%	30.0%	USD

NOTE 32. Post-balance sheet events

No significant events occurred between the reporting date and the date on which the financial statements were authorised for issue by the Board of Directors.

2.2 STATUTORY AUDITORS' REVIEW REPORT ON THE HALF-YEARLY FINANCIAL INFORMATION

(Period from 1 January 2026 to 30 June 2026)

To the shareholders of Exosens,

EXOSENS

18 avenue de Pythagore

33700 Mérignac

In compliance with the assignment entrusted to us by your Articles of Association and decision of the shareholders and in accordance with the requirements of article L. 451-1-2 III of the French monetary and financial code ("*code monétaire et financier*"), we hereby report to you on:

- the review of the accompanying condensed consolidated interim financial statements of EXOSENS, for the period from 1 January 2026 to 30 June 2026;
- the verification of the information presented in the half-year activity report.

These condensed consolidated interim financial statements are the responsibility of the Board of Directors. Our role is to express a conclusion on these financial statements based on our review.

Conclusion on the financial statements

We conducted our review in accordance with professional standards applicable in France.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements are not prepared, in all material respects, in accordance with IAS 34, Interim Financial Reporting, as adopted by the European Union.

Specific verification

We have also verified the information presented in the half-yearly management report on the condensed consolidated interim financial statements subject to our review.

We have no matters to report as to its fair presentation and consistency with the condensed consolidated interim financial statements.

Nantes, 28 July 2026

The Statutory Auditors

PricewaterhouseCoopers Audit	**Baker Tilly Strego**
Anne Parenty Partner	François Pignon-Hériard Partner

03 ADDITIONAL INFORMATION

3.1 STATEMENT BY THE PERSON RESPONSIBLE

“I certify that, to the best of my knowledge, the condensed consolidated interim financial statements contained in this report have been prepared in accordance with the applicable set of accounting standards and give a true and fair view of the assets, financial position and results of the Company and all entities included in the consolidation, and that the attached half-year activity report gives a fair review of the significant events occurring during the first six months of the financial year, their impact on the interim financial statements, the main related-party transactions and the principal risks and uncertainties for the remaining six months of the financial year.”

Mérignac, 30 July 2026

Jérôme Cerisier,

Chief Executive Officer of the Company.

Photo credits
EXOSENS, @Shutterstock, @AdobeStock.

Graphic design and production
Ruban Blanc

EXOSENS
REVEAL THE INVISIBLE

18 avenue Pythagore
33700 Mérignac

www.exosens.com